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ACTIVE SURVEILLANCE AND INCIDENCE RATE OF DENGUE INFECTION IN
A COHORT OF HIGH RISK POPULATION IN MARACAY, VENEZUELA
Carlos Espino, MD., Ph.D. candidate
ABSTRACT
In the absence of an effective vaccine, vector control and surveillance of dengue fever
(DF) and dengue hemorrhagic fever (DHF) are the most important strategies currently
used to reduce the impact of these diseases in affected population. The objectives of this
study were to estimate the incidence of symptomatic and asymptomatic dengue cases, the
prevalence of antidengue antibodies, and to evaluate the laboratory and clinical aspects
related to an active surveillance of dengue cases. In this study, active surveillance was
incorporated as a part of the study design. At total of 3,255 people from four high risk
neighborhoods were followed in a two years prospective study whereby the participants’
houses were visited three times a week. During these visits, dengue cases were
characterized by identifying patients with fever as well as other symptoms that were
compatible with dengue disease. In addition, a biannual blood sample was taken for each
study participants, to establish the prevalence and six month incidence of dengue
infection.
We found a crude incidence density (ID) of 3.24 by 100,000 person/days (p/d) which
changed from 5.69 by 100,000 p/d for the first year of the study to 1.45 by 100.000 p/d
in the second year. In both years, the months from July through September had the
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highest ID of 8.81 by 100,000 p/d. Children displayed higher ID when compared to
adults, RR: 3.92 (2.38 – 6.48).
The Plaque Reduction Neutralization Test was used to assay for the presence of
antidengue antibody in 2,125 study participants (65.3% of total). The prevalence of anti
dengue antibodies was found to be 86.6% (1,840 positives). The prevalence of anti
DENV-1 was 74%, while 65.2 % of the participants had anti- DENV-1 and anti- DENV2 simultaneously. The cumulative incidence of anti IgG dengue antibody in the negative
participants (283 at the start of the study) was 30% in the first 6 months period, 29.6% in
the second 6 months, and 23.8 in the third one.
The difference between the numbers of participants detected in the active surveillance,
(270 confirmed and non confirmed dengue cases) with the numbers of people who
showed sero-conversion to anti-IgG dengue antibody within a relatively short period of
time suggested that there was a high number of asymptomatic dengue infections present
in the population. Transmissibility of the virus, the surveillance of dengue, and vaccine
implementation in the near future would all be affected by the large number of
asymptomatic people in hyperendemic countries.
.

Keywords: Prevalence, asymptomatic, sero-conversion, antibodies, epidemic.
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CHAPTER ONE: THE STUDY PROBLEM
Introduction to the Problem
In the last forty years in the Americas, Dengue Fever (DF) and Dengue Hemorrhagic
Fever (DHF) respectively have been considered a re-emergence and an emergence
disease (OPS, 2000), (OPS, 2006). In the absence of an effective vaccine, mosquito
control and surveillance of dengue disease have been the strategies used worldwide to
prevent this infection. However, 40 years later, the combination of these strategies has
not been totally effective in reducing the number of DF and DHF cases. Dengue virus
(DENV) is spread in all Central and South American countries; all four DENV
serotypes (DENV-1, DENV-2, DENV-3 and DENV-4) are circulating, and the number
of cases reported each year is increasing. A deficient vector control and the type of
ineffective public health surveillance currently being used in Central and South
American countries could partly explain the unsuccessful prevention and control of
dengue (OPS, 1994), (Call et al 2006), (Ooil et al 2006). Usually surveillance is based
only on the passive detection of symptomatic cases and thus does not provide
information about the actual number of people infected, and the true proportion of the
population at risk to get a secondary infection (which is a risk factor of DHF). Passive
surveillance system cannot detect epidemics at a pace rapid enough to provide ample
time for appropriate preventive actions. Furthermore, this type of passive surveillance
system cannot provide an updated analysis related to the dynamic of the dengue disease.
For example, the introduction of a new serotype or genotype could change the expected
1

clinical presentation and epidemiological indicators in the population. Additionally,
this type of information would be essential in the new era of dengue vaccine and
necessary to understand the dynamic of the viral infection. Passive surveillance that
provides only general information such as the number of symptomatic cases reported is
not adequate; alternative options such as active, vector, sentinel and interepidemic
surveillance will have to be globally implemented. (Gubler, 2002), (WHO,1997),
(WHO,1999).
Incidence and Prevalence as measures of Dengue Infection.
In order to achieve a good system of disease surveillance, the epidemiology system
requires specific indicators to be able to calculate and determine the frequency of the
disease. Usually the selected measurement (and/or indicators) depends on the type of
disease. That is how the measure of the dengue infection can be made, which is either to
directly determine the occurrence of their new symptomatic cases (disease incidence) in
a risk population within a given period, or indirectly, to calculate the prevalence of
presence of anti-dengue antibodies in healthy people previously infected in a
determined population. Estimating the infection incidence could be determined by
computing symptomatic and asymptomatic cases of dengue. The disease incidence is
the measure to establish what would be the magnitude of dengue epidemics; what
would be the impact of the problem in terms of public health, and which should be the
best way to proceed to reduce their consequences. The prevalence of antibodies permits
us to know the magnitude of the transmission in a given period, how the virus is
circulating, which age groups are more affected. Furthermore, having two or more
prospective measures of antibody prevalence, we can also estimate the incidence of the
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infection. Through all of these possibilities, early prediction of new epidemics is
reasonably the main goal of many public health programs. (Runge-Ranzinger et al,
2008), (Gordis & Saunders, 2000).
The simultaneous analysis of these two measures of disease and infection permits us
to understand the dynamic of the dengue virus, determine the proportion of
symptomatic and asymptomatic cases, and establish the risk and the factors associated
with the disease.
Historically in dengue disease, Cumulative Incidence (CI) and serological prevalence
of anti dengue antibodies have been the most frequent indicators used to determine the
frequency of clinical dengue disease and dengue infection respectively. Since dengue is
an acute disease, the incidence is the best way to determine its frequency. Since
immunological conversion is a prevalent condition, sero prevalence of anti dengue
antibodies is the best way to determine previous infection of DENV, both usually
reported in surveillance dengue information and through epidemiological dengue
researches (WHO-DENGUENET, 2009).
Considering incidence exclusively, Cumulative Incidence is a good indicator of risk
and the only incidence indicator that can be used to compare temporal and geographical
impact of dengue epidemics. However, its value is not enough to determine factors
associated with the disease. Incidence Density (ID), defined as the number of cases over
the sum of length of time at risk for each participant in a prospective study, is the best
indicator to establish association between factors and disease. Besides, ID is more
precise to estimate the rate of disease occurrence. Due to the fact that ID requires a
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close follow up on the studied population, relatively few studies of dengue have been
reported with this indicator. (Kleimbaum et al, 1982).
In spite of the fact that Venezuela has had the highest incidence of DF and DHF from
1989 to 2005 in the Americas, this country has not studied prospectively exposed
population. There are no reports available to date of dengue researches that use
Incidence Density and also, the studies of sero prevalence of antibodies have been
limited to school children and transversal evaluations (WHO-DENGUENET 2009),
(Guzman, 1999).
Surveillance of Dengue
Public Health Surveillance has been defined by Thacker as: “The ongoing systematic
collection, analysis, and interpretation of outcome-specific data for use in the planning,
implementation, and evaluation of public health practice”. In this definition, the goal is
clear, the steps are logical; however, the procedures of each one of those parts in the
definition can differ among countries, particularly between developing and developed
countries, and can even differ within the same country when comparing data from
different decades. In general, developed countries have better surveillance systems, with
better laboratories for diagnosis, better integration between health service dependences,
and better quality of the data. Gubler, analyzing dengue data generated prospectively,
has been specific about these differences (Gluber, 2002), ( Teutsch and Churchill,
1994).
The choice of which types of surveillance system to use will depend on the
characteristics of the disease, the magnitude of the problem caused by the disease in a
specific country (or global region), and the resource and technology of each affected
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country. In this respect, when analyzing all Latin American countries and Venezuela in
particular, the areas most affected by dengue in the Americas could be considered
developing countries, according to the World Bank classification.. Cuba and Puerto
Rico have demonstrated superior efficacy to control and prevent dengue epidemics. In
the case of Puerto Rico, this country has tried to develop a surveillance system during
inter epidemic periods by implementing a system of the early detection of circulating
viruses, before the epidemic has been recognized (Rigau-Perez, 2005), (Gubler, 2002).
(Guzman, 2005). Venezuela has supported its surveillance system with the passive
reporting of cases; when the number of cases reported is higher than the number of
cases expected; the system can declare epidemic and activate the specific measure of
control. This is the regular application of surveillance in many Latin American
countries, and certainly that is better than nothing, because it has reduced the fatality
from DHF in the last 25 years in the region. (Feldman, 2004).
Clinical symptoms and laboratory diagnosis of Dengue
Diagnosis based on clinical symptoms and laboratory diagnosis of dengue play two
important roles that may be different somewhat. On the one hand, early recognition of
dengue based on the clinical symptoms and early laboratory confirmation could make
the difference between the life and the death of the patient; both of these contribute
towards individual significance of surveillance. On the other hand, clinical symptoms
and diagnosis are also indispensable to detect the presence of the disease and thus could
help to predict and avoid an epidemic. If an epidemic is recognized early, control
measures can be implemented immediately; this represents the public importance and is
the point that is related to the public health surveillance system. (WHO, 1997)
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Statement of the problem
Latin America and many other developing countries do not have a good surveillance
system to detect cases of dengue that are less evident and less symptomatic, whereby
infection of dengue does not yet produce epidemic but may very well be on its way to
generating one.
Specific aspects that could be obtained in these cases include the number of
asymptomatic cases, clinical variations and changes in the criteria for clinical and
laboratory diagnosis of dengue. Additional information that can be acquired include
differences between what regular passive surveillance system is detecting and what
active surveillance system could detect, which and how other risk factors could affect
incidence of dengue and its consideration in an active surveillance system.
Purpose of the Study
The purpose of this study was to establish those epidemiological characteristics,
diagnostic and clinical aspects of dengue disease that could be related with the
surveillance of dengue, and use these to understand how surveillance can be used as one
strategy to prevent the effect of the disease caused by dengue infection. The goal of this
study is to compare and contrast the findings with the traditional or regular dengue
surveillance system. Epidemiological aspects are those indicators which usually are not
considered in the passive surveillance systems but are affecting the dynamic of the
disease in the populations. In this study, epidemiological aspects included are frequency
of dengue, silent or asymptomatically infected people, and the proportion of people at
risk to acquire DHF. Clinical and laboratory diagnostic aspects are those criteria which
can improve the identification of the dengue cases. We considered and collected during
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the course of this study this information, the day of the physical exam was performed and
the blood sample taken, as well as the specific time and type of diagnostic test used and
the clinical symptoms presented. A surveillance system of dengue should have the
capacity to collect and analyze this kind of information in order to prevent disease
effects.
Aims of the Study
1. To estimate the incidence density of dengue disease in the population, by detecting
the number of symptomatic cases during active surveillance, and sorting out and
analyzing data by age groups, location and seasonal year period.
1.1 To estimate the incidence of dengue disease in four neighborhoods.
1.2 To estimate the incidence of dengue disease in children from 5 to 14 years old,
and adults from 15 to 94 years old.
1.3 To establish the Incidence density and compare the Relative Risk of dengue
disease between children and adults.
2. To estimate the prevalence of antibody against dengue in the population using antidengue IgM MAC ELISA and anti-dengue IgG by Plaque Reduction Neutralization
Test (PRNT) using biannual sero-prevalence surveys.
2.1 To estimate the prevalence of antibody against dengue according to specific
serotype and age group.
3. To estimate the proportion of dengue infection through the biannual seroprevalence
surveys, by detecting asymptomatic and symptomatic dengue cases during each interval
of blood sample collection.
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3.1 To estimate the proportion of dengue infection in people with primary and
secondary dengue infection.
3.2 To estimate the proportion of specific dengue serotypes in people tested negative
in the first sero-prevalence sample of dengue antibody (Sample number1).
4. To identify and compare procedure in laboratory test used in the active surveillance,
by considering viremic and immunological indicators at specific time points, which are
categorized based on the number of days after onset of the symptoms, age group,
neighborhoods and serotype from the active surveillance.
4.1 To describe the frequency of blood samples that were taken according to the days
after onset of the symptoms.
4.2 To estimate the proportion of specific dengue serotype by age group of patients,
and looking for possible association between these parameters.
4.3 To estimate the proportion of specific dengue serotype by four neighborhoods,
looking for possible association between these parameters.
4.4 To estimate the number of cases detected by specific type of diagnostic test, and
the day of sample taken after the onset of the symptoms.
4.5 To compare the results of confirmed dengue cases determined by Active
Surveillance with the same samples tested using PRNT, and establishing the
proportion of congruency between temporal and specific dengue serotype.
4.6 To compare the results of IgM MAC ELISA test in confirmed dengue cases by
Active Surveillance with the same samples tested by PRNT, looking for the
proportion of primary and secondary infection according to IgM test results.
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5. To identify clinical symptoms according to disease confirmation and age group in
those people who were detected in the active surveillance.
5.1 To describe the most frequent symptoms present in all people detected to be
dengue positive by the active surveillance as designed in the study.
5.2 To compare the most frequent symptoms between confirmed and non- confirmed
dengue cases as detected by the active surveillance.
5.3 To identify those symptoms and hematologic indicators associated with
confirmed and non confirmed cases by the active surveillance.
5.4 To identify hematologic indicators of dengue and anti-dengue IgM antibody in
consecutives samples during acute phase of dengue disease in people detected by the
active surveillance.
6. To identify the differences between the regular system of passive surveillance of
dengue disease in the national and local department of health and the data obtained in
this study, assuming this study represents a system of active surveillance.
6.1 To determine diagnostic classification according WHO in the study data.
6.2 To describe the cumulative incidence of dengue in 2007 related with the seasonal
rainy months.
6.3 To describe the cumulative incidence of dengue in 2007 related with the passive
national and local surveillance of dengue.

Significance of the Study
In dengue, surveillance is a recognized preventive measure to control the disease.
However, few studies have been conducted to determine which specific aspects of the
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dengue disease can be used to improve that surveillance system. This is particularly true
in developing countries where the disease is hyperendemic, and where many control
activities have had little impact in controlling the increasing numbers of epidemics. The
goal of this study is to identify some of the aspects within an active surveillance design
that can be applied in a real community, and which include children as well as adults as
the study subjects. Apart from our study, we could not find any prospective study
focusing on the communities that conducted weekly door to door visits and which take in
consideration a broad range of age, when we reviewed more than 75 articles searched
through PubMed that reported prospective studies of dengue. Most of these studies were
conducted either in schools or workplaces, or using community health services. Besides,
these studies were usually focalized in a specific age group, which are either children or
adults, but not both.
With dengue vaccines continually being developed in different phases of study but still
elusive, the precise knowledge of virus transmission and early detection of cases is
becoming extremely necessary in the effort to work towards prevention of dengue
diseases.
This study will contribute towards increasing the knowledge pertaining to dengue.
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CHAPTER TWO: BACKGROUND AND LITERATURE REVIEW
Dengue Disease: General Characteristics.
Worldwide, dengue is the most important viral disease transmitted by mosquitoes and
other arthropods, with an estimation of around 100 million cases and 20,000 deaths
annually (Stephenson, 2005). Dengue affects tropical areas of Asia, Africa, Oceania and
the Americas. The causal agent is the Dengue Virus (DENV), which belongs to the
Flavivirus genus, and is transmitted mainly among humans by the species of
mosquitoes Aedes egypti and Aedes albopictus (Fields 2001), (Kuno 1997). For more
than 200 years, this infection has been recognized causing important epidemics in the
Americas, Africa and Asia. However, Dengue Fever (DF) or also known as classical
dengue was not considered a fatal disease until the 1950’s when it appeared in South
East Asia as a new, severe and fatal variant of dengue disease known as Dengue
Hemorrhagic Fever (DHF). Even though a few hemorrhagic cases of dengue had been
described before 1950, these cases had never occurred as an epidemic. Therefore since
that time, DHF is considered an Emergence disease (WHO, 1997), (Isturiz et al, 2000),
(Gubler 1995), (Pinheiro 1997).
Clinical presentation of dengue is described as an asymptomatic infection until severe
and fatal Hemorrhagic and shock syndrome, passing by mild like viral syndrome and
non fatal Dengue Fever. (WHO, 1997).
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Without an effective vaccine and antiviral treatment for dengue, control of the vector
and surveillance are the only two most important public health strategies to prevent and
control this disease and its consequences. (Stephenson, 2005), (WHO, 1999).
Supported by established theories, dengue disease could be considered as one of only
a few viral human diseases where previous infection by heterologus dengue serotypes
increases the risk to a developing a new, severe and sometimes fatal dengue virus
infection. (Rico-Hesse et al, 1997), (Gubler, 2002).
Dengue Virus.
Dengue virus is a positive sense single strand RNA virus, belonging to the family
flaviviridae. This family has three genera: Hepacivirus, Pestivirus and Flavivirus.
DENV is a flavivirus which belongs to a genus with more than 70 viruses, including
two phylogenetic groups: the mosquito borne with West Nile Virus (WNV), Saint Luis
Virus (SLE), Yellow Fever Virus (YFV), Murray Valley encephalitis virus, Kunjin
virus and Japanese Encephalitis Virus (JEV) and the tick borne with Powassan virus,
central European encephalitis virus and Far Eastern encephalitis virus. (Fields, 2001),
(Mukhopadhyay et al. 2005).
The dengue virion consists of an envelope and nucleocapsid, and is spherical with a
diameter of 40-60 nm. The RNA complete sequence is around 10,700 nucleotides long.
(ICTV, 2009). The genome encodes three structural proteins (capsid, pre-membrane and
envelope) and seven non structural proteins (NS1–NS2A–NS2B-NS3-NS4A– NS4BNS5). Due to polarity and exposition, the majority of the primers to identify and
differentiate DENV to other flavivirus target the Envelope and NS1 regions. Primer
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regions usually are related with the pathogenesis and cross reactive immunity of the
viruses (Kuhn et al, 2002).
Dengue virus is subdivided into antigenic types according to serological criteria and
four serotypes have been recognized: Dengue virus 1 (DENV-1), Dengue virus 2
(DENV-2), Dengue Virus 3 (DENV-3), and Dengue Virus 4 (DENV-4). Each serotype
produces lifetime immunity against homologous dengue viruses, and temporary and
partial immunity against heterologous dengue viruses. (WHO, 1997), (Fields, 2001),
(Kuno, 1997).
Depending on the area of the world, the cross reactivity among the flaviviruses plays
a key role in specific antibody identification and surveillance system. This crossreactivity among flavivirus species can be causative of false positive in serological test
results. In Asia, Japanese encephalitis and West Nile infections are the main cause of
cross reactive immunological response in dengue laboratory surveillance. Yellow fever
has the same importance in Central and South America, while West Nile and Saint Luis
Encephalitis viruses are more prevalent in North America (Mukhopadhyay et al 2005),
(Koraka et al 2002). In addition, cross reactivity can be generated by vaccination of
YFV live attenuated and JE inactivated virus. (Scharwtz et al 2000), (Vasquez et al,
2003).
Based on the nucleotides substitution rates estimation of Dengue virus, mean
substitution rates are in a range from 4.55 x 10-4 (DENV-1) to 9.01 x 10-4 (DENV-3)
substitutions per site, per year; therefore, the origin of DENV could be relatively recent,
at around approximately 1,000 years ago.(Twiddy et al., 2003).
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Anti DENV antibodies have been found in non human primates in West Africa and
Asia (Malaysian), supporting sylvatic transmission cycle idea for Dengue viruses.
Indirectly, this provides evidence that dengue originated from monkeys and sylvatic
mosquito vectors. At some point in time, the virus passes to the humans; this probably
occurred approximately 200 or 300 years ago (Holmes, 2003), though othershave
related the origin of dengue disease with former cases reported from China and French
West Indies (Gubler,1998). Supposedly, the disease was effectively spread to the
Americas when the virus and its mosquito vector ( Aedes species) were transported in
slave trading or other commercial trips from Africa either during the XVIII century or
before. Even when two cycles (sylvatic and non-sylvatic) of the DENV transmission
are recognized, clinically and epidemiologically, dengue transmission is considered a
human to human infection disease. Therefore, in contrast to other vector-borne diseases
and especially arthropod viral diseases, dengue does not have other hosts or reservoirs
to facilitate or anticipate the action of public health surveillance. DENV can grow in
monkeys and mice but these animal species do not exhibit symptoms of the disease as
seen in humans (Holmes et al , 2003), (Pang, 2003), (CDC-DHHS, 1993).
Disease Transmission and Vector.
Dengue infection is transmitted from human to human through the bite of female
mosquitoes. During the viremic phase, infected humans are capable of transmitting the
virus to the mosquitoes taking in a blood meal. This viremic phase in human blood lasts
approximately 5 days and takes place after one incubation period of 6-8 days; this is
known as the “intrinsic period”. After mosquito bites an infected human while taking a
blood meal, the viruses propagate inside the vector during the “extrinsic incubation”
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period, which usually lasts 7 to 8 days. Finally the infected mosquito re-feeds and
transmits the virus to a second susceptible human (WHO, 1997), (McBride et al, 2000).
The virus human cycle is limited at 3 -5 days due to a cytopathic humans cells effect;
this cytophatic effect does not occur in mosquito where the viruses can be propagated
and accumulated in the salivary gland throughout the lifetime of the mosquito. (Fields,
2001). After a mosquito gets infected, it is capable of, and is effectives in transmitting
the Dengue virus to the next human host and cause dengue infection. In addition,
experimental studies have demonstrated that mosquito to mosquito transmission by
vertical transovarial infection is possible. One study demonstrated the capabilities of
seven mosquito generations passing the virus. This could be a way to keep the virus in a
place without the direct infection of humans (Joshi et al, 2002). Besides, Mourya found
DENV in aedes aegypti eggs and the vertical transmission rate was higher in those eggs
with more time to hatch. (Mourya et al, 2001).
Aedes aegypti and Aedes albopictus are the two most important mosquitoes capable
of transmitting the Dengue viruses and infecting humans. Both mosquito species are
present in the Americas and Asia where dengue is a public health problem. However,
Aedes aegypti has demonstrated more efficiency for dengue viral transmission. This
advantage is related to the capacity of A. aegypti to live within the human communities,
sharing resting areas and using the stored human consumption water as a feeding
habitat. All the life stages of this mosquito can be developed within the human habitat;
this behavior is different when compared to A. albopictus which is a more aggressive
vector which sustains feeding habitats farther away from human houses. Consequently,
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A. aegypti has been considered to be the principal vector, and A. albopictus the
secondary vector in the transmission of dengue (Kuno 1997), (Nagao et al, 2003).
In the absence of an effective vaccine against dengue, control of the mosquito vectors
which is based o elimination of larvae and breeding ground sites more than the adult
mosquitoes control, is the key to prevention of the disease and the epidemics. However,
in many developing countries, the current vector control emphasis is in emergency
response rather than prevention of epidemics. This is illustrated by the emphasis on
adult mosquito elimination, which corresponds to an emergency response approach,
versus larvae elimination which unfortunately is not perceived as a great control
measure since the impact is not immediate.(Gubler, 1998). The best examples to
illustrate the point above are represented by these countries where the focus of
prevention has been the mosquito control; United State in the last century, Cuba after
1981, and Singapore in the last 25 years (Wilder-Smith et al, 2004), (Halstead, 2000).
Of course, mosquito control by use of chemicals such as insecticide is not the only
method for an effective vector control. Other approaches that could also be very
important include ways such to improve the housing conditions, education of people at
risk, and improvement of water system supply in the community so as to reach a
definitive prevention of this disease (Heukelbach et al, 2001), (Gubler, 2002).
In addition to the control of vector to prevent disease, mosquitoes can also play a
significant role in conducting the dengue disease surveillance. The measures of the
larvae or mosquito density are indicators to identify areas of greater risk. Breteau index
has been classically been one of the most used method to estimate relative densities of
mosquito. Breteau index is defined as the number of positive containers (Aedes aegypti
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larvae that can be visually detected) per 100 houses inspected. House Index is another
indicator that can be used to estimate the mosquito density; it is defined as the
percentage of households infested with larvae or pupas in a specific urban or rural area.
Another aspect of the dengue vector surveillance that poses a challenge is the fact that
dengue does not have other hosts that can be used to detect or predict, during the early
stages that the virus is circulating in the community. In other words, beyond knowing
the density of the mosquitoes in terms of determining the entomological risk, and
identification of dengue viruses and their specific serotypes in these mosquitoes; these
would be the only invaluable measures that can provide information about circulating
dengue viruses during the interepidemic periods. In the United State the mosquitoes
surveillance for both purposes. However in developing countries, the mosquitoes’
surveillance when it does take place is used only to determine the density of the
mosquito (CDC- DHHS, 1993).
Transmissibility
The transmission dynamic in dengue disease is the result of many variables. This is
due to a combination of actions by four independent serotypes, and the different ways
the disease is presented into the variety of environmental conditions. The four serotypes
have the capacity to circulate simultaneously in hyperendemic areas where secondary or
tertiary infections can be potentiated by previous heterologous serotypes and non
neutralizing antibodies. The majority of infections are unapparent or asymptomatic even
though some clinical cases can be severe. Information from the literature does not
describe if the asymptomatic cases have the same transmission capacity than patients
presenting with dengue symptoms. This concern is expressed in this quote “Another

17

problem rarely addressed in BRR determination is the impact of asymptomatic
infections” (BRR: Basic Reproductive Rate). (Kuno, 1997).
Basis Reproductive Rate (Ro/BRR) also known as Basis Reproductive Number, is
the average number of new infections produced for each case of current infection. This
indicator helps to determine how a disease infection can spread throughout the
population. When Ro is higher than 1, the infection is able to spread in the population,
and if Ro is less than 1, epidemiologically the infection will die out. In addition, BRR
has public health importance as it can be used to establish the proportion of population
that needs to be vaccinated to reach herd immunity. The higher the BRR, the higher the
proportion of people that needs to be vaccinated. According to Kuno, the range of
dengue BRR would be from 1.33 to 2.00, though recent studies show that the numbers
can be greater. BRR is in direct relation with the number of contact per unit of time,
transmission probability per contact and duration of infectiousness. (Kuno, 1997),
(Massad, 2003).
Special situations can occur with DENV transmission; DHF cases could increase
when vector prevention control partially reduces the mosquito density. In his study,
Thamalato concluded that the negative relationship between DHF incidence and dengue
transmission intensity implies that in regions of intense transmission, insufficient
reduction of vector abundance may increase long-term DHF incidence. (Thamalato et
al., 2008). Singapore provides another example of a situation of dengue transmission
that is difficult to understand. This country has been successful in reducing the
mosquito density; however, simultaneously they have had an increase of dengue fever
cases in the last years. (Egger et al, 2008). In other viruses the infection transmissibility
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could be explained easier but not so for dengue as it is almost like four diseases that is
closely linked by a confused immunological system.
Herd Immunity
Herd immunity is the resistance of a group or community to attack by an infectious
disease due to the fact that a large proportion of the population is immune against the
disease. This term is usually associated to vaccination effect; however, having the
disease is a way to acquire “natural” immunity and theoretically acquire herd immunity.
Herd immunity threshold is the maximum level of immunity beyond which
transmission is eliminated (Kuno, 1997). There is not only a meaning to this concept,
John and Samuel proposed one interesting differentiation: herd immunity as “the
proportion of subjects with immunity in a given population” and “herd effect” defined
as “the reduction of infection in the unimmunized segment as a result of immunizing a
proportion of the population”. (John & Samuel, 2000).
In any case, herd immunity is closely related to the Basic Reproductive Rate. Massad
in Brazil showed 64 cities with dengue epidemic; all these cities had BRR greater than 1
with a range from of 2.74 to 11.57. The maximum value in Brazil is similar to the BRR
of Measles infection viral disease which required between 83% and 94 % of vaccine
coverage. Ferguson in Thailand obtained BRR to four serotypes using different
methods; the range of values was from 1.39 to 7.73 but they did not find differences
among serotypes. (Massad, 2003), (Ferguson, 1999).
When we check the different mathematic models proposed in studies to estimate the
Basic Reproductive Rates, these are based on the number of cases that started the
epidemics, known probabilities of human to mosquitoes contact, and the number of
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susceptible at a certain time. However, probable effect of asymptomatically infected
people in the transmission is not clearly represented in these mathematical models.
(Koopman and Longini, 1999), (Kuno, 1997).
Epidemiology and Surveillance of Dengue
Worldwide Distribution
Historically, there are at least three different sources providing report about the first
dengue case; chronologically, a report from China provided the first description of a
disease compatible with dengue in 610 A.C. (Gubler, 1998). The second report probably
registered the source of dengue outbreak was in West French Indies in 1635 (Izturiz et
al, 2000), (Gubler, 1998). Finally, and usually the most cited first dengue report was
about dengue in Philadelphia in the summer of 1779 (Gubler, 1995), (Holmes, 2003).
There is disagreement about the the origin of the dengue virus, reported to be either
from Africa or Asia. This is due to non-human primates that were detected with DENV
in the sylvatic cycles in both continents; and is not clear which was the direction of the
expansion. (Holmes, 2003).
There were at least 4 Dengue-like illness epidemics in the Americas that happened in
the XVIII century occurred (Pinheiro et al, 1997). Asia had similar evidence of nonfatal disease with epidemics of 10-40 years intervals (Gubler, 1995). The negative
effect of the World War Two in the South East Asia environment was probably the
event which separated the benign dengue disease from the severe and sometime fatal
dengue. Hyperendemicity and expanded DENV epidemics in the region were the
prelude to the first confirmed epidemics worldwide of Dengue Hemorrhagic Fever,
which later became established as an emerging global disease. The exact event that
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started all of this was thought to have occurred in Manila Philippines in 1953–1954,
(Gubler, 1998). However, according to Halstead, non confirmed DHF epidemics had
already previously appeared in Australia in 1897 and in Greece (western hemisphere) in
1928, (Halstead, 1980). After the 1953 epidemic of Manila, the DHF spread throughout
all of Asia, beginning by the south east countries and extending to the rest of Asia.
The first report of an epidemic of Dengue Hemorrhagic Fever (DHF) in the Americas
occurred in Cuba in 1981, whereby 158 people died and 10,300 DHF cases were
registered. The second large epidemic took place in Venezuela in 1989 with 2,665 DHF
cases, extending to 1990 with 3,325 DHF cases, whereby 18 and 52 people died
respectively, in those two years of outbreak. According to WHO-DENGUENET, since
1960 to 1980, Cuba and Venezuela were the two countries with the most number of
dengue fever reported to WHO; in Cuba the highest number of DF cases occurred in
1977 (477,440 cases) and in 1978 (75,692). Venezuela had three peaks of DF cases;
18,306 in 1964, 7,750 in 1966 and 100,000 in 1978. (WHO-DENGUENET, 2009).
However, after the epidemics described above, Cuba and Venezuela followed different
paths reporting different epidemiological histories. Cuba did not have cases reported
again after the earlier epidemics until 1997, when Cubans suffered a second epidemic
which characteristically affected only adults. On the contrary, after 1989, Venezuela
became the Latin American and Caribbean country with the greatest number of DHF
cases, whereby many people died from dengue disease. Other countries also have had
higher incidence of dengue but none has had worst indicators in terms of magnitude
(Kouri et al, 1998). According to the Antibody Dependent Enhancement theory, DHF
could be directly correlated to hyperendemicity. This could explain the high number of
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DHF cases in Venezuela, specifically in Maracay which is the capital of the Aragua
State, where geographical studies has demonstrated the simultaneous circulation of all
dengue serotypes.(Rico-Hesse et al, 1997), (Barrera et al, 2000).
Incidence of Dengue
Incidence means new events or cases happening within a period of time. In
epidemiology these new events are referred either in relation to the population at risk, or
in relation to the population-time at risk. As a result, incidence of a disease could be
measured by two ways. One way is determining the Cumulative Incidence (CI) which is
estimated by calculating the proportion of people who developed the disease in a fixed
and disease-free population at the beginning of the follow-up period. Frequently, the CI is
the indicator used either by the regular system of surveillance, or by the public health
programs inserted in a national or international communicable disease network. CI is
obtained considering new cases detected in annual periods of time. Theoretically,
Cumulative Incidence can measure the risk and predict risk in an individual level. The
other way to obtain incidence is by determining the Incidence Density (ID) which is
defined as the instantaneously change of disease status per unit of time. The ID
determination requires the amount of population-time (PT) added by each person in the
study. PT can be expressed interchangeably in years, months, days and hours. ID can
estimate rate referred to a population thus it does not have direct interpretation on the
individual level. (Kleinbaum, Kupper and Morgenstern, 1982) (Rothman, 1986). The
Incidence Density is mostly used by Researchers who are looking for association among
factors and the frequency of the disease.
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Through DENGUENET, World Heath Organization has the most complete historical
database about the amount of dengue cases represented by the three more affected
regions in the world: Pan American Health Organization (PAHO) in the Americas, South
East Asia Region, and Western Pacific Region in Asia. (WHO-DENGUENET, 2009)
According to data of PAHO in the period from 2000 to 2005, the highest Cumulative
Incidence of dengue (by 100,000 population) in the Americas has consecutively been in
French Guiana (1,001), Costa Rica (343), Honduras (254), Barbados (221), Brazil (195),
San Vincent (158), Suriname (154), Venezuela (143), Puerto Rico (92), Colombia (82),
Paraguay (81), Ecuador (72) and El Salvador (68). Considering the period time from
1980 to 2005 and dividing into two sub periods: one from 1980 to 1996 and the other
from 1997 to 2005, it is important to indicate that Brazil and Costa Rica have had more
than 80 % of their cases after 1996, compared with Venezuela, Colombia and Honduras,
which reported having similar number of cases in both the 1980 to 1996 period as well as
in 1996 to 2005 period. (WHO-DENGUENET, 2009).
In the South East Region of Asia and in the same period from 2000 to 2005, the
highest CI of dengue were in Maldives, Thailand, Sri Lanka and Indonesia with 113, 109,
37 and 26 dengue cases by 100,000 population. In Western Pacific Region, Palua,
French Polynesia, Cook Island, Northern Mariana Island and American Samoa had more
than 1,000 cases by 100,000 populations. Malaysia had CI of 82.8 while Singapore had
368, but only in 2005 (WHO-DENGUENET, 2009).
In dengue disease, one of the first prospective studies was performed by Burke et al. in
Thailand in 1980. They followed 1,757 students between the ages of 4 to 16 years old,
and obtained two blood samples within an interval period of six months. Febrile students
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were always tested in acute and convalescent stages. 103 (5.6%) were infected in the 7
month study period and 90 out of these were asymptomatic children. Seven students were
hospitalized with DHF and all of them had previous antibodies against dengue. (Burke et.
al.1988). A second follow up three year study was performed in Thailand in 2002; this
time 2,214 school children made up the cohort. The overall incidence was 5.8 %, and out
of them 3.1 % was in Asymptomatic dengue virus infection and 2.7% in symptomatic
dengue. The incidence of dengue was gradually declining in the three year study from 7.9
% in 1998 to 6.5 % in 1999 and down to 2% in 2000. They found similar incidence
between symptomatic and Asymptomatic infection, contrary to the conclusion in other
studies.(Endy et al. 2002). Other incidence study was performed in adults in Bandung,
Indonesia. Incidence Density was calculated; contrary to Endy et al conclusion, they
found 56 per 1,000 person-day dengue infection in asymptomatic people versus 18 per
1,000 person-days in symptomatic cases. Even in areas without symptomatic cases, they
found incidence density of 8 per 1,000 person-days in asymptomatic people. (Porter et al
2005). Other prospective study was performed in Indonesia in 1995, reporting an
incidence of 29.2 % in the year of follow up. All febrile cases in this study were
secondary infection (Graham, 1999). In Vietnam where a study on 977 school children
was conducted, an annual incidence of 11.7 % of dengue primary infection was estimated
by binary regression of the sero-prevalence by age. In a second part of the study two
years later, the sero negative school population (831 children) was newly tested with 30.6
% of sero-converted, and then the true annual incidence of primary dengue was 17.5%.
(Thai et al, 2005), (Thai et al, 2007).
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In the western hemisphere less numbers of prospective studies have been reported.
However, incidence of dengue has been published from different region of epidemics.
The Puerto Rican 1994-1995 epidemic presented an incidence of 7.01 per 1,000 people
increasing from 2.55 per 1,000 people annual average incidence in the last 4 years from
1991 to 1994 (Rigau-Perez et al, 2001). Teixeira in a prospective study in Salvador,
Brazil reported an incidence of 70.6 % of dengue infection but it was significantly higher
in those people previously tested positive with one serotype (83.0% ) than those people
previously tested negative (60.8%), (Teixeira et al, 2002). Balmaseda et al in Nicaragua
in a two year follow up study found 12% of dengue incidence the first year, decreasing to
6 % in the second year (Balmaseda et al 2006). In Brazil, where the incidence of endemic
disease included dengue, it was studied in the Amazon region. The average incidence of
dengue from 2001 to 2005 was 185 per 100,000 populations, which is very similar to that
registered by DENGUENET in all of Brazil (195 per 100,000 population) in a similar
period from 2000 to 2005 (Penna et al 2009).
Sero-prevalence of Dengue.
Most of the epidemiological studies in dengue have been performed to determine
which proportion of the population has been previously infected by the dengue virus,
which age group is more affected and which dengue virus serotypes are present in the
population. Single transversal sero-prevalence surveys and prospective sero-prevalence
studies have been designed to reach those goals. In Indonesia in 1995, 1,837 children
from 4 to 9 years old were studied. Dengue serotype antibodies prevalence was estimated
twice during a one year interval. At the beginning of the study, 56.1 % of the children
were positive to dengue antibodies, 12.0% were immune to DENV-1, 16.3% to DENV-2,
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2.2% to DENV-3, 3.8% to DENV-4, and 21.8% were immune to two or more serotypes.
The prevalence of two or more serotypes increased from 37.2 % in the 4 year old children
to 69.7 % in 9 year old children. At the end of the study, 26.8 % of the sero-negative
children seroconverted; the children with primary infection in the cohort study (Graham
et al 1999). Similar study was performed in Vietnam but with an age group of children
from the ages of 7 to 14 year olds. The dengue serotype antibodies prevalence increased
from 53 % for the 7 year old children to 88 % in the 13 year old children. (Thai et al,
2005). In Singapore, a cross sectional seroprevalence study was conducted to estimate the
proportion of adult people (18 to 45 year old) with anti dengue antibodies 133 of 298
(45%) enrolled participants were tested positive. The prevalence increased with the age
group from 17 % in the group of 18 to 25 year old, to 44% and 74% in the groups of 25
to 35 year old and 36 to 45 year old, respectively. Singapore is one of the few Asia
countries which have been able to reduce the incidence of dengue cases. (Wilder-Smith et
al, 2004).
The study of Teixeira in Brazil presented a seroprevalence of 68.7%. The lower value
was 39.0% among 0 to 4 year old children and the greater value was 76.4 % among 30 to
39 year old adults. Also, this study showed variation from 16.2% to 97.6 % among 30
areas in Salvador, Brazil. (Teixeira et al 2001). In Dominican Republic, 98 % of the
1,008 adults recruited in blood bank and 56 % of the children less 10 year old visiting a
Hospital in Santo Domingo were tested positive to IgG anti-dengue. Among children, the
prevalence of antibodies increased by age (Yamashiro et al 2004). A seroprevalence of
dengue in children less than 11 years old found a prevalence of 19.9% of dengue
antibodies. They compared children living in coastal area with children living in inland
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area. The prevalence in coastal area was 36.9 % significantly higher than inland area
which was 2.9% (Iturrino-Monge et al, 2006). The prospective study made by Balsameda
et. al in Nicaragua presented one of the greatest prevalence of dengue antibodies in
children (4 to 16 year old) of the Americas. The overall prevalence was 91%, increasing
from 75% at age 4 to 100% at age 16. (Balmaseda et al, 2006). Some areas in the
Americas show low prevalence of dengue antibodies; one study in Tabasco Mexico was
performed by enrolling university students between the ages of 18 to 39 year old. The
prevalence of dengue antibodies was 9.1 %. Interestingly, the prevalence of anti DENV-1
antibody was 20% and 100% and 68% of antibody against anti DENV-2 and DENV-4
respectively. (Sanchez et al, 2008). In Maracay, Venezuela, a prospective study was
performed on 710 schoolchildren from 5 to 13 year old. The Prevalence of anti dengue
antibody was 51 %.; 30.1 % were tested with immune response to one serotype, and
20.9% to two or more serotypes. The highest dengue type antibody prevalence was
DENV-2 with 14.2% followed by DENV-1 with 13.4%. 25.6% of the children
seroconverted among all previously sero-negative children, and 26% of the children
seroconverted in children with secondary infection. (Comach et al. 2009).
Surveillance of Dengue
Public Health surveillance is defined, according to Thacker and Berkelman as: “Public
Health Surveillance is the ongoing systematic collection, analysis, and interpretation of
outcome-specific data for use in the planning, implementation, and evaluation of public
health practice.” (Thacker & Berkelman, 1988). However, this concept has undergone
several changes through the time, until the middle of the last century the emphasis was on
the contacts of sick people with a communicable disease. Now surveillance is addressing
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to the risk factors and other health-related events like accidents, injuries, chemical
exposure, and infection disease vectors. New features have also improved the concept,
classifying the surveillance into the categories of passive and active. In a Passive
Surveillance System, the disease case (or other health-related events) notification is
dependent on information retrieved from inferior levels of public (or private) health
institutions. In an Active Surveillance System, the central department of health contacts
regularly the health services to ask about (or look directly for) disease cases or other
health-related events. In accordance with Teutsch, surveillance data can be used in the
following ways (among others):
“To estimate the magnitude of a health problem
To understand the natural history of the disease
To detect outbreaks or epidemics
To document the distribution and spread of a health event
To monitor changes in infection agents.” (Teutsch & Churchill 1994) (CDC, 2001).
CDC in 2001 presented the Updated Guidelines for Evaluating Public Health
Surveillance Systems with the purpose to ensure that public health problems are
monitored efficiently. Also the CDC considers evaluation of traditional surveillance
attributes including: simplicity, flexibility acceptability, sensitivity, predictive positive
value, representativeness, timeliness and stability. However; depending on the highest
priorities in the health, related event could change the importance of each attribute. Other
interesting aspect in this document is the concept of Preventability defined as: ”From the
perspective of surveillance, preventability reflects the potential for effective public health
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intervention at any of these levels” (Primary, Secondary and Tertiary levels). (CDC
2001).
In dengue infection these theoretical concepts have been adapted to the disease
characteristics. PAHO in its scientific publication No.548 links Active Surveillance with
laboratory-based surveillance, in the effort to understand the low sensitivity of clinical
dengue parameters in non epidemic periods. This document also defines different levels
of surveillance depending on epidemiological situations: countries where no dengue cases
have been detected but where the vectors are present, countries where dengue is endemic,
and countries where dengue is epidemic. Viral laboratory support is most important
where dengue is endemic and less important where there are no dengue cases (PAHO,
1994).
In health services, the final goal of any kind of surveillance is prevention. Depending
on which level of the natural history of disease the health service wants to emphasize, it
will represented by the type of surveillance action employed. For example, if a country
wants to totally prevent disease and eradicate cases, then that country has to focus on
eliminating those risk factors which facilitates the disease as the first level of prevention.
In dengue disease, this control could be achieved with the surveillance of density vectors,
feeding vectors, water supply service and, human household conditions. This kind of
surveillance or risk surveillance is exceptionally implemented in developing countries.
These actions are regularly implemented in a developed country; even though dengue
would not be the exclusive focus of the intervention effort.
In dengue endemic areas, other levels of surveillance would need to be set in place in
preparation to detect any early increase circulation of the dengue virus, through increase
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in virus activity either within vectors or through detection of the first human cases during
an interepidemic period. The goal would be to predict the incensement of the human
cases to avoid epidemics. Active Surveillance would be the best way to reach this goal. In
this case, early control measure will be applied and the epidemic would be avoided.
Developed countries would not need this kind of surveillance but developing countries
do, but only a few can maintain this system because it requires an advanced viral
laboratory. (Gluber, 2002).
Also, in dengue endemic areas situated within a country that lacks organization and
equipment to actively look for either early disease cases in interepidemic period or
positive vectors to virus infection, the system has to wait passively for the dengue cases
to be registered and analyzed. This approach is known as a Passive Surveillance system,
whereby it would be too difficult to predict and avoid epidemics from happening. As a
result, the goal has to shift towards to reducing impact of the epidemic as a secondary and
tertiary level of prevention, reducing the Fatality Rate, preparing the health services and
hospitals, eradicate the vector, and training health workers and population to handle the
epidemic situation.

This is the usual the approach adopted in many developing

countries facing the threat of dengue. (Gluber 2002).
Laboratory and Diagnosis.
The clinical manifestations of dengue are represented by symptoms that are specific
to dengue make the diagnosis of this disease difficult. Additionally, in periods of no
dengue epidemic, the sensitivity of the symptom identification is much lower. As a
result, laboratory confirmed tests become necessary procedures and tools to diagnose
dengue. Another important aspect of dengue laboratory is the high frequency of
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asymptomatically infected cases, which are commonly detected by sero-prevalence
surveys. Asymptomatic infections impact the knowledge of the virus transmissibility
and new serotypes introduction. In surveillance, laboratory support is one of the
cornerstones of the system; efficacy in the dengue diagnosis is closely related to the
dynamic between the dengue viremia and the immune response in primary and
secondary infections. Viremia is present in the blood patient at the moment of the onset
of symptoms (usually fever) and could be present for more than three or five days
which would be during the time the virus is detected. The end of the viremia usually
marks the beginning of the immune response. The duration of the immunoglobulin in
blood will depend on their type: IgM antibody will be in blood for 80 to 90 days and
IgG antibody for life. (WHO, 1997).
Therefore, there are two basic procedures to establish laboratory dengue diagnosis:
the detection of the virus and the detection of the antibody.
Viral Isolation.
Viral Isolation is the most sensitive way to detect DENV. Three techniques can be
used: 1. Mosquitoes (pool of 15 to 20) are inoculated either with serum, or plasma, or
pleural fluid or other sterile body fluid. Days after, virus infection is confirmed by
immunofluorescence. This is the most sensitive isolation technique. 2. Inoculation of
mammalian or insect cell cultures (usually C6/36) is other common used for viral
isolation. The presence of the viruses is confirmed by cytoptathic effect or plaque
formation assay. RNA detection and immunofluorescence also can confirm the infection.
3. Intracranial inoculation of sucking mice is the third way to isolate dengue virus; either
encephalitis signs or antigen in brain tissue are evidence of infection. The higher
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limitation of the Viral Isolation is that this method ise time consuming, and also there is
high cost associated with use of of the cell culture method. (WHO 1997).
Polymerase Chain Reaction and Dengue Virus.
A relatively new molecular technique, Polymerase Chain Reaction (PCR) was
developed to amplify DNA fragments. Later, a variant of that technique has also
permitted amplification of RNA through a cDNA intermediate; this advanced technique
has had direct consequences in the diagnosis of RNA viruses. Reverse Transcriptase–
Polymerase Chain Reaction (RT-PCR) test has reduced the time of diagnosis of dengue
disease, while keeping a good level of sensitivity for the purpose of detection. RT-PCR
method requires for reaction to start with the reverse transcription from RNA to a
complementary DNA (cDNA), using the enzyme reverse transcriptase. The PCR step that
follows reverse-transcription has three parts all performed in a thermal cycling instrument
(which would be the same as performing traditional PCR with DNA as the starting
material): 1. Denaturation of the DNA, increasing the temperature to melt the double
stranded DNA into single strands , 2. Annealing the target DNA with specific primers by
decreasing to an optimal the temperature and finally, 3. Elongation is the extension of the
DNA from the primers, increasing the temperature according to specific DNA
polymerase. This step should be repeated between 20 to 40 times to get the ideal
amplification of the DNA fragment. In dengue, RT-PCR was initially used with a nested
two step protocol (Lanciotti et al 1992). Later, an improved version of the test was
designed which reduced reaction time, using a single tube multiplex RT-PCR (Harris et al
1998). In both cases, all four Dengue viruses can be detected. (McPherson et al, 1999),
Raengsakulrach et al. in 2002 compared four RT-PCR procedures in Thailand where all
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serotypes of dengue are circulating and need to be detected and distinguished from one
another. The method developed by Henchal et al. amplifies the 482 nucleotide sequence
in the NS1 region of the dengue virus genome. The method of Morita et al, utilized four
pairs of type-specific primers to detect simultaneously the dengue serotypes. And the
methods of Lanciotti et al. and Yenchitsomanus et al. employed universal dengue primers
followed by a type-specific nested PCR. The sensitivity, considering serologically
confirmed cases, was 54, 52, 60, 79 % respectively with the indicated methods
(Raengsakulrach et al, 2002).
A new advance in PCR and RT-PCR was the introduction of the real time analysis
detecting amplified products during the process of the DNA amplification, using
fluorescent based reporter chemistries. Comparative advantages comparing real time to
conventional PCR and RT-PCR are; Real Time RT-PCR is less time consuming, is more
sensitive and the viremia can be estimated quantitatively. Oliveira in Brazil compared
RT-PCR with Real Time RT-PCR, finding better sensitivity in Real Time RT-PCR. They
concluded that a good way to detect and diagnose dengue is by combining Real Time
RT-PCR during the first days after onset of the symptoms with serological detection of
anti IgM dengue antibody in later days of acute phase. (Oliveira et al, 2005). These are
important advances in Public health surveillance system whereby laboratory diagnosis of
dengue can be made from patient samples from any day during acute disease. To
establish the viremia is important in studies to relate blood levels of viruses and
pathogenesis through the different cells and cells products in infected people.
In 2004, Lemmer et al. showed a study of external quality assurance (EQA) of 13
laboratories which apply RT-PCR and Real Time RT-PCR in dengue diagnosis: only two
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laboratories received the maximum score of quality, and only four detected low dilution
of RNA dengue in samples. In their recommendation, the authors said that eight of
thirteen laboratories should improve the sensitivity and specificity of the test (Lemmer et
al, 2004). Oliveira et al compared five RT-PCR kits (two Two-Step kits and three OneStep kits) and found clear advantage using One-Step kits to detect low dilution of viruses.
The problem of short duration of virus presence in the blood of patients would be
resolved with the use of non-structural dengue antigens, because of the long persistence
of these antigens in the blood (Schilling, 2004).
Serological Test.
The use of immunological test is based in the immunological response after being
exposed to an external agent such as virus. For the purpose of laboratory diagnosis,
humoral response detecting antibody would be the most important criteria to consider in
diagnosing dengue infection. Immunoglobulin G (IgG) and immunoglobulin M (IgM),
each one or in combination, are usually the key factors to be detected in the diagnosis
either of past dengue infection (IgG) or acute primary and secondary infection (IgM and
IgG). A definitive diagnosis of acute infection requires a pair of samples, which need to
be collected during the acute and convalescence phase. In addition, a secondary infection
can be demonstrated if the ratio IgM/IgG is less than 1.5. In dengue, this would be
possible because each type of immunoglobulin levels can rise for two or four weeks after
infection, depending on the kind of infection. If a patient had a primary contact with the
virus, the IgM will be expected to present with higher levels in blood; while in a
secondary infection the IgG in blood will be higher (WHO, 1997).
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Haemagglutination Inhibition Assay (HI), Complement Fixation (CF), Neutralization
Test (NT), Indirect IgG Enzyme Linked Immunosorbent Assay (ELISA) and IgM
Monoclonal Antibody Capture Enzyme Linked Immunosorbent Assay (MAC-ELISA) are
some of the tests used in serological dengue diagnosis. (WHO, 1997).
For many years HI was the most used test in the routine dengue diagnosis, due to its
high sensitivity and relatively low cost. Characteristically however, this test does not
distinguish between immunoglobulin isotypes. As a result, for HI, absence or low level of
antibodies in the acute phase with increased level in convalescence phase is considered to
be the indicator of primary infection in dengue disease. In addition to this shortcoming,
HI is not a serotype specific test for dengue (Teles et al 2005).
NT is the test with highest specificity in dengue infection and contrary to HI, is
capable of discriminating the virus serotype in primary dengue infection; though, this
would be difficult to determine in secondary and tertiary infections (Morens et al, 1985).
NT has an advantage related to its specificity and it is usually necessary in studies of
sero-prevalence and prospective design. However, this test is laborious, expensive, and
time consuming in those clinical scenerios where quick results are needed.
Since 1987, IgM capture ELISA (MAC-ELISA) test has been recommended by WHO
to be used in the diagnosis of acute dengue disease. Having a slightly higher sensitivity
than HI, MAC ELISA is also more specific with less cross reactivity to other flaviviruses.
This test becomes positive five or six days after the onset of the symptoms. The day of
conversion when the antibody could be detected is extended to more days after the onset
of symptoms in secondary dengue infection, whereby also a smaller proportion of
patients appear to be negative. (Gubler et al 1998).
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Indirect IgG ELISA test is a sensitive test to determine the chronic prevalence of anti
dengue antibodies but is less specific and with higher cross reactivity to other
flaviviruses.
Guzman et al. showed the report for external control proficiency test of dengue
serological diagnosis in the Region of the America in the period 1996-2001. Twenty
seven laboratories received 54 serum panels. The result showed that 95.6 % of the
antibody IgM tests were concordant with the result from the reference center. In
conclusion, they summarized that the majority of the participating laboratories showed
excellent performance for diagnostic capabilities (Guzman, 2003). Donoso et al. in 2002
evaluated laboratories in Europe, in a program of External Quality Assurance, with
combination of different panels of IgG and IgM antibodies (+ and +, - and +, - and –
,etc.). They found correct results in 88% of the IgG-positive samples and for 100% of the
IgG-negative samples, 91 % of the IgM-positive samples and 97% of the IgM-negative
samples. (Donoso 2004). One of the problems of serological tests is the differentiation
among flaviviruses which is very important in countries where many of these flaviviruses
are co-circulating simultaneously with dengue virus. (Koraka et al, 2002), (Cuzzobbo et
al, 2000), (Scharwtz et al, 2000). As a result, some studies compare ELISA techniques
(Palmer et al, 1999) that could distinguish these different flaviviruses. Cuzzobbo et al.
compared PanBio Dengue Duo Igm and IgG Capture ELISA and Venture Technologies
Dengue IgM and IgG Dot Blot. One of his most important conclusions was that in
countries with high prevalence of co-circulating flavivirus, PanBio ELISA performed
better because this test was able to avoid false positive results. (Cuzzobbo, et al, 2000).
On the other hand, those countries with low prevalence like the USA DotBlot ELISA
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would be a good choice as dengues test kit, because it can detect any case of dengue, thus
avoiding false negatives. Another innovation with PanBio duo ELISA is to
simultaneously measure IgG and IgM in the same test. According to Sang et al, the
sensitivity, 99%; specificity, 96% of this technique was superior to the use of IgM alone
or IgG alone, 88 % of sensitivity and 96 % of specificity, and 85% of sensitivity and 96%
of specificity, respectively. (Sang et al, 1998). Oliveira found more sensitivity in MACELISA compare to PCR when this test is performed in the 5 and 6 days after onset of the
symptoms. In addition, Chanama et al. compared IgM antibodies in primary and
secondary infection; specific IgM was detected in all the cases with primary dengue virus
infection on disease day 9 or later. However, specific IgM cannot be detected in 28%
(204 / 716) of the cases in secondary infections. They recommended other test for
confirmation in all secondary infections (Chanama et al, 2004).
One of the weaknesses of serological test is the necessity of using two samples from
the acute and convalescence phase of infection to confirm the disease. In addition, the use
of invasive technique which is the need to take blood samples, would be another factor
that is considered problematic. In this sense, it is of significant interest for some studies
to apply less or use of a non- invasive procedures for sampling such as taking saliva
samples. These studies have found a good correlation between IgM in saliva and IgM
serum. One of these studies also included IgA in this saliva-serum comparison, but the
result showed that these antibodies were better detected in serum. (Balmaseda et al,
2003), (Cuzzobbo et al, 1998).
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Clinical Manifestations.
The clinical characteristics of Dengue disease can be different according to the kind of
disease presentation. The dengue infection could be asymptomatic as detected through
expressed immunological response, or symptomatic. Symptomatic patients may have
undifferentiated fever like a viral syndrome, Dengue Fever (DF) Syndrome (with or
without hemorrhagic manifestations) and Dengue Hemorrhagic Fever (DHF). DHF with
shock is also known as Dengue Shock Syndrome (PAHO, 1994).
According to WHO, a clinical case of Dengue Fever is an acute febrile illness with
frontal headache, retroocular pain, muscle pain, joint pain, and rash; even though other
signs and symptoms could also be presents (such as lymphadenopathy, petechiae, nausea,
hepatomegaly, and different types of hemorrhagic). A probable case of DF is defined as
cases with fever and two or more of the following manifestations: headache, retro-orbital
pain, myalgias, arthralgias, rash, hemorrhagic manifestation and supportive serology (HI,
IgG, IgM tests) or occurrence at the same location and time as other confirmed cases of
dengue.

A confirmed case of DF is defined as cases with isolation of dengue virus for

serum or autopsy sample; or demonstration of fourfold change in reciprocal IgG or IgM
antibody titers in paired serum samples; or demonstration of dengue virus antigen in
autopsy tissue, serum or cerebro-spinal fluid samples by immunohistochemestry,
immunofluorescence or ELISA; or detection of virus genome sequence in in autopsy
tissue, serum or cerebro-spinal fluid samples by RT-PCR. Hemorrhagic Dengue Fever
case has to have all the four following criteria: Fever, hemorrhagic tendencies (including
tourniquet test), thrombocytopenia (100,000 per mm3 or less) and plasma leakage
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(hematocrit >20%, signs of plasma leakage: pleural effusion, ascites and hypoproteinemia) (PAHO,1994), (WHO, 1997).
Pathogenesis of Dengue Hemorrhagic Fever.
The pathogenesis of hemorrhagic dengue fever that has been described has many
implications in the understanding and control of this disease, as it relates to efforts to
identify people at risk. Basically, at least two theories have been presented to explain
the severity of DHF. (McBride et al, 2000), (Halstead et al 1977): 1. According to the
first theory of Antibody dependent enhanced (ADE), previous antibodies of a specific
serotype of dengue virus bind to different dengue virus serotype producing non
neutralized antibody–virus complexes. These complexes bind to macrophages which
lead to activation of T cells from previous presentation to Major Histocompatibility
Complex molecules (MHC). Cytokine production then becomes the a consequence of T
cells activation: Interferon-γ, Tumor Necrosis Factor, IL1, IL6, IL8 (Yang et al, 2001),
Fernandez et al 2004), (Huang et al, 2000), (Talavera et al 2004). Additionally,
Vascular Endothelial Growth Factor (VEGF) is produced by monocytes and endothelial
cells (Tseng et al, 2005). Among other effects, it produces changes in the wall of
capillaries with hemorrhagic symptoms and leakage of fluid in the body cavities that
could end in death of the patient. 2. According to the second theory, specific genotypes
of dengue virus which are more virulent could cause of more severe symptoms of
dengue (Rico-Hesse et al, 1997). Probably both theories are correct and complement
each other. Epidemiological studies show the relationship between severity of
epidemics and previous serological conditions of the population affected. Sequence of
infection with DENV-1 virus followed by DENV-2 has been demonstrated to correlate
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with high rates of DHF (WHO, 1999). However, differences in the severity and number
of DHF cases have been demonstrated when the strain of the DENV-2 virus is Asian or
American, with the latter one being less virulent (Rico-Hesse, 1990).
Prevention and Control.
Worldwide, one of the challenges of the public health is the search for effective
methods to control dengue disease. For decades, either in the Americas or Asia, WHO
has made recommendations about the best way to prevent dengue epidemic. Throughout
this time, the essence of the WHO’s effort is the same, though the strategies to reach
this goal have continually changed (WHO, 1997), (PAHO, 1994), (WHO, 1999), (Parks
et al, 2004). Unfortunately, most of these of strategies have only generated very poor
results (Gubler, 2005), (Calisher, 2005), (Gubler, 2002).
There are three approaches to prevent dengue disease and dengue epidemic: 1. To
block the virus action inside the human hosts with use of vaccine to induce specific
immunization. 2. To halt the infectious chain reducing or eliminating the vector:
mosquito control. 3. To detect the cases and the virus in early periods of viral activity
by epidemiological surveillance either to reduce or prevent the impact of the epidemic
(PAHO, 1994).
These three activities should not work independently. However, the focus and
intensity of each application can depend on the moment of infection, the location (world
region or country), and the budget in health and the specific type of disease infection.
For example: the focus of Yellow Fever prevention in South America is the vaccine and
surveillance of human cases and monkeys, and secondarily, the mosquito control. For
one specific disease, the same sentinel animal could not be good in all areas of one
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country or region (PAHO, 1994), (CDC, 1993). In addition, these three strategies can be
(more or less, depending of each one) affected by other important factors such as
education, family income, housing conditions and social services (water supply and
waste disposal). For example: housing condition (without window screen) affects more
the mosquito control than a massive vaccination campaign.
The uncontrollable worldwide activity of dengue virus and its vector deserves a short
analysis of each strategy of prevention. In dengue, the vaccine is already being
developed. However, an effective vaccine is yet far from being available for public use.
In general terms, this challenge of an effective vaccine selection is due to the presence
of multiple serotypes and their interactions with the heterotypic antibodies. In
particular, it has been difficult to measure the amount of virus and its immunological
response in different situations. Serum Neutralization, a very specific and sensible test
to make these measurements, has presented with problems to standardize procedure
using these four different serotypes. Many authors have always been worried about the
risk that the dengue vaccine could be the prime vaccine for development of DHF by
Antibody Dependent Enhancement (ADE) which makes the infection worse, instead of
providing protection. Furthermore, a good animal model for dengue is lacking whereby
in many cases, in the existing animal model systems showed that these animals can be
infected but do not develop the symptoms of the disease (Stephenson, 2005), Pang,
2003), (Calisher, 2005).
Mosquito control has been shown to be the best strategy to prevent dengue epidemic.
This was evident during the time when the Americas was free of dengue in the period
(1940’s and 1950’s decades) of control and almost eradication of Aedes aegypti, as a
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plan of yellow fever control. Re-infestation in the sixties, of Aedes aegypti permitted
entry of new dengue virus serotypes in the Americas (PAHO, 1994). Other historical
example was the campaign against the mosquitoes and their breeding sites carried out in
Cuba after the huge epidemic of 1981(Guzman et al, 2005), (Kouri et al, 1998) which
permitted for a period of 16 years without dengue to take place in that island. Singapore
is the Asian example of the same result with the same strategy; this small but rich
country could reduce the index of Aedes aegypti to levels apparently secure, and reduce
almost totally the cases of dengue (Wilder-Smith et al, 2004). This strategy is based on
the reduction of breeding sources (Essentials as storage water and Non essentials as
tires and waste), larvae and adult mosquito control, surveillance of vector, community
education and personal protection. These two countries which represent two opposite
political models have been the best examples of successful mosquito control strategy.
However, this strategy though good, has not been perfect in any of these countries. As
an example,n 2002 Singapore had a dengue epidemic with unthinkable low density
levels of mosquitoes, and with a high number of risk population with low level of herd
immunity as a result of many years without epidemics. A similar situation occurred in
Cuba in 1997 when DHF affected only adult population who had been in contact to
dengue virus in 1981, or before. No child born after 1981 was reported with DHF in the
1997 epidemic. This finding could explain two aspects of dengue situation in Cuba; the
relationship between secondary infection and DHF, and the success in the control of
Aedes aegypti for more than 15 years. (Gubler, 2002), (Kouri et al, 1998). Something
however is true in that neither Singapore nor Cuba could avoid a new epidemic of
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dengue. Both events indicate that the dynamic of dengue virus and its vector is complex
and cannot be reduced to only one strategy or a single program in Public Health.
Recognizing the little advance in the control of dengue, the last WHO's
recommendations focused on community participation in the programs of prevention
and mosquito control in dengue (Parks et al, 2004), (Suhaili et al, 2004). However, we
can see how this suggestion was so general in 1995, more specific in 2002 and very
specific in 2004 when WHO includes COMBI (Communication for Behavioral Impact)
plan and textual analysis say: “Knowledge is not enough, Evaluation researchers have
noted that, despite growing levels of knowledge and awareness about dengue and
mosquitoes, many people are still not taking action.” And “Many programs continue to
focus only on changing people’s knowledge and on raising awareness, believing that
behavior will change.”
The success of this strategy depends on the continuity of its implementation, either in
the period of epidemic or during the inter-epidemic periods. In many developing
countries, several of these activities of control are activated in the periods of epidemic,
acting as tertiary prevention but not as primary prevention in public health, like a
disease control focused on emergency response. Gubler stated that emphasis is on
emergency response rather than more on prevention (Gubler, 1998).
The third general strategy in the prevention and control of dengue is the surveillance.
In many developing countries, surveillance is part of the epidemiology department in
the services of public health. However, most of these countries have the passive system
of surveillance (Gubler, 2002), (WHO, 1999. It means that the case of dengue is
registered when the patient goes to the health service center. However, if for any reason
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the patients with dengue fever or DHF do not go to look for medical attention, they will
never be recognized by the system. It is clear that in passive surveillance the cases with
diagnostic will be those with more obvious and florid disease. Asymptomatic cases or
mild cases could not be detected (Endy et al, 2002). Developing countries with passive
system of surveillance use this system to detect epidemic and activate measures of
control and attention of patients in hospitals. For active surveillance, the goals can be
different. The objective of active surveillance is to predict the epidemic instead to detect
it. In active surveillance, is important to detect any case of dengue and not only the most
florid case. In addition, the role of active surveillance is more important in interepidemic periods where laboratory confirmation is essential (clinical criteria can be
enough in epidemic stage) (Rigau-Perez, 2001), (Gubler, 2002). According to Gubler,
few countries in the world have capacity to do an active surveillance; he summarized
these countries in this category: Singapore in Asia and Puerto Rico and Brazil in the
Americas, which are countries with adequate laboratory resources to sustain an active
surveillance system. Active surveillance in Puerto Rico has permitted the prediction of
all the epidemics since 1998 with only one wrong prediction in 2003. Gubler says that
in Puerto Rico the rainy cyclical population of Aedes aegypti has not been historically
affected by programs of mosquito control, as a result, this characteristic supports the
emphasis that Puerto Rico has created and sustained the active surveillance system of
dengue (Gubler, 2002). In an infectious disease as dengue without other animals or host
to detect early the circulation of the virus and consequently to activate epidemiological
alarms, the system has to be very sensitive to detect the first human cases. Ideally, the
virus needs to be detected two, three or four weeks before the evident ascend of the
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epidemic. At this time the identification of the dengue case has to be very precise, and
any gap or doubt in the case definition could affect the success of the active
surveillance. The study of Endy et al in Thailand showed around 50 % of the cases of
dengue could be asymptomatic and others are mild symptomatic (Endy et al, 2002).
This is important if we see that World Health Organization promotes very specific
criteria to define a dengue case (WHO, 1997). These criteria would leave out many
asymptomatic and mild cases of dengue. Besides, confused procedures recommended
by WHO avoid a better detection of cases. WHO recommends taking two blood
samples: one in the acute phase and one in the convalescent phase, marking 10 days as
the ideal time between the two blood samples. We have shown in un-published data
how more than 90 % of the cases in a regular surveillance system have access to only
one sample, with low percentage of confirmed cases of dengue. We have also shown
that the tendency in the last years is to reduce the days to take the blood sample after the
onset of the symptoms, from 6 in 1998-1999 to 4.5-5 in 2000-2002. Maybe this
tendency has been promoted for the interest in taking blood sample in the times when
viruses can be detected. The big problem is that 4 to 5 days could be too late to detect
RNA from the virus and too early to detect immunological response. (CDC Puerto
Rican branch). Also, few patients would return for a second blood sample, reducing
highly the number of case confirmation because a hypothetical second sample could
identify elevations of antibodies from nothing in the first one (WHO, 1997). Therefore,
it could be reasonable to recommend taking two samples in the acute phase: the first
sample in the first three days of fever to detect the RNA and the second one after day
number 6 after onset of symptoms to detect the immunological response. With this
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condition, if RNA is detected, the case is confirmed. However, if RNA is not detected,
two samples after day 6 looking for immune response will be necessary.
We can summarize the limitations of a regular passive system of surveillance as such:
1.Passive surveillance can estimate incidence of symptomatic cases of dengue but not
incidence of infection (symptomatic, mild symptomatic and asymptomatic cases). It has
particular importance because a first exposure to dengue virus is a significant risk factor
to get HDF. 2. Passive surveillance waits for the cases, usually florid cases; some
cases will never be detected if the system does not look to detect for these cases. 3.
Passive surveillance is not concerned about the prediction of an epidemic of dengue
with a prudent time to avoid it; the role would be to detect the cases over the epidemic
to activate inter-sectors responsibilities: mosquito control, hospital, media and
community. 4. Passive surveillance is not concerned about the identification of the
prevalence to specific serotypes of dengue virus in population at risk to a new epidemic
with new serotype or genotype. 5. Passive surveillance cannot identify changes or
variant in the clinical presentation of the cases that could be affected for the
introduction of new serotypes or genotypes.
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CHAPTER THREE: METHODOLOGY
Design
In order to achieve our objectives, a Longitudinal Panel Study Design. (Hybrid
Studies) (Woodward M. 2005) was developed and implemented. A close tracking of
people at risk for dengue was required to detect information that is usually hidden in the
natural dynamic of the dengue disease. One strategy employed was routine visits of
families recruited in the study, and inquiring about fever and other risk factors that could
be related with dengue so as to determine the best way to describe unknown
characteristics of this disease. Individuals who were recruited to participate in this study
were from different four neighborhoods and lived in their designated family houses. The
cohort was followed after the initial demographic questionnaires were completed, and
determination of sero-prevalence of dengue antibodies was made. Three visits a week
were made by nurses who asked participants about fever events experienced by
individuals studied. If any case of fever was detected, a clinical and laboratory evaluation
was performed by physicians. This portion was named the active surveillance in the study
design. Besides, each six months sero-prevalence surveys of dengue antibodies were
repeated in a procedure that was called biannual blood samples. A smaller or sub-cohort
of people with clinic diagnosis of dengue determined according to the WHO criteria,
were invited to participate in a special part of this study describing clinical and laboratory
changes during the period of acute disease. This part of the study also required having
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blood samples taken at 24, 48 and 72 hours of fever period, and 24 and 48 hours after
fever disappears, but only in those confirmed dengue cases.
All dengue cases were described monthly within the two years and three months
study period. This duration of study period permitted us to compare the incidence in this
study with the state and national incidence of dengue disease. Simultaneously, we were
also able to compare the traditional passive model of the state and national surveillance
with our design which, in some sense, reflected an active surveillance system to detect
dengue disease.
Incidence Density (ID)
With the purpose of obtaining the Incidence Density, we computed the number of
days per months for each individual who participated in the study. We obtained the total
of person-days either per months or trimester or year. The report of days began the day
that each person is included in the study, and was completed when he or she left the
study by any of these three possible causes: 1.When the person died. 2. When the
person left the study before it is over, and 3. When the person left the study at the time
the study is over. The number of person-days was also distributed by neighborhood, by
age group, and by gender. The Incidence Density was calculated dividing the number of
confirmed dengue cases by the total number of person-days, in general, or by specific
groups. This number was then multiplied by 100,000, and expressed by 100,000 persondays.
ID Relative Risk was calculated to age groups and gender, by dividing ID in children
less than 15 year old by ID in adult people equal or higher than 15 year old, and
dividing ID in females by ID in males.
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In order to compare our data with the state and national surveillance, we had to
calculate the Cumulative Incidence in 2007 because this is the measure used in passive
surveillance. We divided the number of dengue cases detected in the active surveillance
during 2007 by the total number of people who began and finished the study within the
365 days of 2007.
Population and selecting a sample.
For this study, Venezuela was the reference country. In 1989 Venezuela had, after
Cuba, the second largest epidemic of DF and DHF in the Americas. Aragua state, where
this study was performed, was one of the most affected areas in Venezuela. Aragua
state is located in the central north of Venezuela, with the Maracay city as its capital.
(Appendix A and Appendix B). This study was conducted in four neighborhoods
located within the city of Maracay. In Maracay, the range of temperature is between 25
and 35 º Celsius, and for the most part, the city is situated around four hundred fifty
meters over the sea. The mean total precipitation in Maracay is between 3.5 mm in the
dry months to 179 mm in the rainy months. (Appendix C). The target population
included in the regular surveillance system is represented by approximately one million
six hundred thousand people. From this population, around thirty six percent (576,000)
are less than fifteen years old. In Maracay and its metropolitan area, there are about one
million people. Aragua state has eighteen municipalities and six of these are parts of
Maracay’s urban and suburban areas. Two hundred and nine local primary health
centers are distributed in all of the state, and these are the first places utilized for dengue
cases detection. When the dengue case is suspected, the specific characteristics of
dengue disease according to the WHO recommendation are recorded, and then one
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blood sample is taken for each case. Each epidemiological municipality center collects
the information and reports to the epidemiological department of the state health
service, and sends the sample to the central laboratory of infections disease in the state
(LARDIDEV). The Laboratory performs specific tests for dengue case confirmation
according to recommendation of the World Health Organization. The highest risk areas
of dengue are in the urban and suburban neighborhoods of Maracay. Four
neighborhoods (known as “Barrios” in Spanish) with the highest incidence of dengue
cases in the last years were selected for this study. In the next step, each neighborhood
was divided into blocks or squares of approximately 125 houses or families, and then
one of these blocks in each neighborhood was randomly selected. The total number of
families ended being around 500 with a total of approximately 2,500 subjects.
According to previous studies conducted in Maracay, we were expecting a 14 % lost of
subjects per year.
The sample size of 2,509 subjects was obtained by assuming a hypothetical high
incidence of 15 %, and an estimation error of 3 % from the target population, with a
confidence interval higher than 95 % (alpha 0.05). This calculation was made using
EPIINFO program, to determine sample size for population survey. We established a
number of around 500 individuals by each neighborhood except in the highest
neighborhood called “Cana de Azucar” where we selected 1,000 individuals with 500
participants in each two separated sections of this neighborhood. The individuals lost
during the study were replaced by 746 people who entered into the cohort in 2007 and
2008 (Table 1). The criteria to replace people were either someone who is a family
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member of the study population, or neighbors living in the same blocks of the people
studied.
Table 1.
People enrolled in the cohort study during 2006 and 2007 according to their
Neighborhoods and age group.
Neighborhoods
(Barrios)

Age
Group

23 de Enero

<15
≥15
<15
≥15
<15
≥15
<15
≥15
<15
≥15

Caña de Azúcar
Cooperativa
Piñonal
The Four
Neighborhoods
Total

People enrolled in
the initial
Cohort in 2006
100
402
212
794
134
367
108
392
554
1955
2509

People enrolled
in 2007

Total

93
98
82
211
41
86
42
93
258
488
746

193
500
294
1005
175
453
150
485
812
2443
3255

Collecting data
In the block of houses of every neighborhood, we started by visiting each family
inviting them to participate in the study. If the family wished to be in the study, one
informed consent had to be signed for each member after a clear explanation of the
study was provided. Each member of the family was free to participate independently
of the other member’s decision. When every family had its first visit, and the
demographic and risk factor questionnaires were completed the first blood sample was
taken from each member of the family. After this first visit and during the duration of
two years and three months, the family was visited three days weekly, whereby they are
asked about fever incidence of any family member. If any family member had fever, a
blood sample was taken and a clinical evaluation was made. Blood Sample collection
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was performed as follows; venipuncture was performed by an experienced phlebotomist
followed by drawing 5 ml of whole venous blood from an antecubital vein from each
adult, and 3 ml from each child ages 5-17. The blood was collected in one Vacutainer®
collection tube (red top) without anticoagulant. Sera were separated by centrifugation at
2,500 rpm, transferred to cryo-vials and stored at -20ºC.
This weekly activity looking for febrile cases was named the active surveillance
component in the study.
Persons presenting signs and symptoms consistent with dengue disease were invited to
participate in a sub sample which was subjected to higher numbers of hematologic test. If
the specimen was RT-PCR positive for dengue virus, additional blood samples were
collected at 24, 48, 72 and 24-48 hours post fever defervescence, and 30 days post initial
sample. Serology was tested in all sample and RT-PCR from 0 to 72 specimens. Ten ml
of whole venous blood were obtained from each patient, collecting in one Vacutainer®
collection tube (purple top) with anticoagulant.
In the same period of the study, we were collecting the information of dengue cases
reported in the regular surveillance system from the health department of Aragua state.
This data will be compared with the level of the neighborhood, the municipalities and
the state.
Instruments of data collection.
1. Questionnaire of the First Visit: this instrument will include:
1.1. Demographic Information: Age, gender, number of members by family.
2. Serology, blood Sample taken to detect antibodies. (IgM MAC ELISA and IgG by
PRNT). (Appendix D).
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2.1. In the first visit: Time zero.
2.2. Following biannual visits: Each 6 month.
3. Card Family Visit (three times a week) in Active Surveillance component.
3.1. Registering family members with fever.
3.2. If somebody has fever: blood sample was taken for diagnosis of dengue and
clinical
evaluation.
4. Sub-cohort card of symptomatic cases of dengue, invited to participate in this study
component.
4.1. Blood samples of dengue diagnosis: 0, 24, 48 and 72 hours during fever period
and 24 and 48 hours after fever defervescence, and 30 days post initial sampling..
4.2. Clinical description.
Laboratory Analysis
IgM MAC ELISA: Sera were tested for anti-dengue antibodies. The ELISA antihuman IgM antibodies were coated onto 96-well microtriter plates. Aliquots of diluted
serum were added to each of the anti-human IgM antibody coated cells, followed by
one hour incubation.
PRNT: Test sera were diluted two fold in the media (EMEM) from 1:5 to 1:5,120.
200 µl media with 40 to 80 PFU of assay virus was mixed with 200 µl diluted test
serum and then incubated at 4º C for 15 hours. In triplicate, 100 µl virus-sera mixture
were added to 0.5 ml media containing 1.5 x 105 BHK21 cells and then added to a 24
well tissue culture plate, and incubated at 37 º with 5% CO2 for three hours. The cells
were then overlaid with overlay media and incubated at 37 º with 5 % CO2 for 5 days.
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Following incubation, the media were removed and the cells were stained with stain
solution Naphthol Blue Black, sodium acetate and Glacial Acetic Acid by 30 minutes.
Stain was removed and the plaques were counted. The results were expressed as the
serum dilution that reduced the number of plaques by 70% compared to that of normal
human serum at the same dilution.
RT-PCR: Viral RNA was prepared fro 140 μl sera using QIAamp Viral RNA Mini
Kits following the manufacture’s instructions. Nested dengue virus RT-PCR was
performed following the protocol of Lanciotti et al.
Processing Data
In order to analyze and describe the result, the data was distributed by each
neighborhood. Initially the age of the people was classified in three ways: 1. Eighteen
age groups of 5 year intervals, from 5-9 to 90-94. 2. Three age groups; less than 15
year old, equal or higher than 15 and less than 50 year old and, higher than 50 year old,
and 3. Two age groups: less than 15 (called children in this study) and equal and higher
than 15 year old (called adults in this study). The first two age distribution was made to
acilitate demographic comparisons. However, due to the fact that most of the studies
have made their age distribution similar to the children - adults’ classification, most of
the analyses were made almost exclusively with the two age groups distribution. We
use the femininity ratio (RT) to see the gender distribution according to the age groups
and the four neighborhoods in the study.
In order to describe the exact number of days of each participant and their type of
permanency in the study, the participants were classified in five groups. Type I: people
who never left the cohort. Type II: people who only left the Bi-annual blood sample to
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obtain prevalence of antibodies but not left the active surveillance. Type III: People who
left and came back to the cohort. Type IV: people who definitively left the cohort,
active surveillance and Bi-annual sample. Type V: people who died for other causes,
but not due to dengue. This approach was taken to see the impact of the different causes
that made the people leave the cohort according to their frequency, age groups, gender,
residence, and person days in each months of the study.
The crude Incidence Density was attained in the two year period and was adjusted
(direct method) by age (children/adults) and gender of the Maracay city population. ID
was also calculated by each year in the study and by months and trimester of each year.
We obtained ID by neighborhoods, age-group and gender simultaneously.
Incidence Density Relative Risk of dengue was calculated in the two year study,
associating age-groups (children versus adults), and gender (female versus male).
IgM anti-dengue antibody was tested (MAC ELISA) each six months in all study
individuals to establish its prevalence as a percentage. This percentage was obtained
with the positive number of people to IgM, dividing by the number of people tested.
IgG anti-dengue antibody was tested by PRNT. All prevalence were calculated by
determining the percentages of monotypic antibody (for each four serotypes), and
multitypic antibodies with two, tree and four antibodies simultaneously, and all
combination of serotypes detected. The percentages of people with negative results
were also obtained. These results were analyzed according to the year (2006-2007) and
age-group (children/adults and each 5 year intervals). The percentages of seroconversion were also calculated into the three intervals of the four biannual samples:
{between the first sample (S1) and the second sample (S2)}, {between the second
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sample (S2) and the third sample (S3)} and {between the third sample (S3) and the
fourth sample (S4)}. Simple Proportion test was applied to establish the difference in
the percentage of infection among negatives and infected people, and monotypic
infected and multytipic infected people Simple proportion test was also applied to
compare difference between samples in each group of negatives, monotypic and
multytipic infected people.
A model of Nominal (Binary) Logistic Regression was made to estimate the relation
between the infection by dengue virus in a period of six month, considering the sample
2 (S2) as a dependent variable and as independent variables or factors: previous
infection in time cero (the first sample at the beginning of the study) and sample 1 (S1)
at the first six months, age, sex, residence (neighborhoods), beginning of the study
(cohort 2006 or 2007), number of serotypes in time cero and sample 1 and interaction
variables between age and sex, residence and age, cohort and age and cohort and sex,
with a confidence level of 95% The infection in sample 3 (S3) was not used as a
dependent variable because the number of lost people was higher that last sample.
In the patients detected by active surveillance, confirmed cases were defined as those
patients with clinical manifestation of dengue according to WHO and positive RT-PCR;
probable cases as those patients with clinical manifestation of dengue, positives IgM
and negative RT-PCR. Finally, negative cases were those patients with clinical
manifestations of dengue but negative in RT-PCR and IgM.
The people detected by active surveillance were analyzed by case definition,
residence, serotype, age-group, and days of diagnosis after the onset of the symptom.
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Independence among categorical variables was tested with Chi square test with a
confidence level of 95%.
Percentage of specific symptoms and signs were obtained in people detected in active
surveillance distributed by age group, and by confirmed and non confirmed cases.
Independence among categorical variables was tested with Chi square test with a
confidence level of 95%. To confirm the statistical results by bi-variable test and adjust
them by age group, gender and residency, logistic regression analysis was applied with the
symptoms and signs of the people detected in the active surveillance.
Additional tests were done in a sub sample of patients during the acute and
convalescence phase of the dengue disease, including: hemoglobin, hematocrit, platelets,
white blood cells, lymphocytes and neutrophils. Statistical differences among these
hematologic quantitative variables were tested with Student T test and F test when was
compared between confirmed and non confirmed cases, and Student T matched test when
consecutive samples were made.
Acute and convalescence sero-conversion to IgM anti-dengue antibody was evaluated in
those patients confirmed with dengue by RT-PCR.
To do comparable analysis of the active surveillance in this study with the passive
surveillance in the local and national system, we redefined the terms of confirmed cases of
dengue. In this part of the analysis people detected in active surveillance with clinical
manifestation of dengue and positive IgM sero-converted in the convalescence phase of the
dengue disease were considered confirmed cases. Besides, for similar reasons, cumulative
incidence was calculated in the sample studied. The comparison between both surveillance
systems was made in the year 2007 exclusively.
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Ethical consideration.
The confidentiality of all participants will be maintained throughout the study. All forms
with identifiers will be maintained in a limited access office at the BIOMED. In the
reporting of the laboratory results, names were used, but the information was only provided
to the head of the household or the attending physician. All demographic, clinical,
epidemiological, and laboratory data on each sample were entered into a database by the
unique identification number. The risks of infection with venipuncture sampling were
minimized by using only trained personnel to perform the venipuncture procedures using
sterile, single use needles, alcohol/betadine wipes and bandages. All official protocol files
(protocol, IRB minutes, and approvals) were maintained at the NMRCD under password
protection. All consent forms and questionnaires will be maintained in the BIOMED,
Maracay, with copies provided to NMRCD and stored under limited access.
Informed Consent Process: Wellness visits/longitudinal cohort: in selected Barrios, a
study representative was knock on prospective participant’s doors, identified them self
and described the study. If the head of household was interested in participating, they
gave a blank consent form and the representative returned in 3-5 days, allowing time for
the household members to discuss the study, to enroll the household if the household
members agree to participate. The enrollment process included reading the informed
consent document (ICD) to the potential subjects followed with the potential subjects
reading the ICD and signing it, for children and adults. (Appendix E and Appendix F).
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CHAPTER FOUR: RESULTS
Demographic Description:
A total of 3,255 people aged 5 to 94 years old were recruited to participate in
longitudinal study. Enrolled people were followed during two years in four
neighborhoods (Barrios) of Maracay, Venezuela. The barrios selected were: “23 de
Enero” including 693 (21.3%) people, “Caña de Azucar” with 1299 (39.9%) people, “La
Cooperativa” 628 (19.3%), and “Piñonal” 635 (19.5%). The goals were to detect acute
dengue cases in an active surveillance of fever and dengue symptoms, and to identify
antibodies anti-dengue virus with biannual blood samples. According to the age group
dividing in children and adults, 784 people (24.1%) were children (among 5 and 15 years
old), 1,721 (53.9%) adults equal and older than 15 and less than 50 years old, and 750
(23.0%) were adults equal and older than 50 years old. (Table 2).
Table 2.
Demographic Features of the enrolled people, distributed by Barrios, gender and age groups < 15
year of age, ≥ 15 < 50 and ≥ 50 years of age.
Neighborhoods (Barrios)
23 de Enero

Caña de Azúcar

La Cooperativa

Piñonal

Gender

<15

Female
Male
Sub total
Female
Male
Sub total
Female
Male
Sub total
Female
Male
Sub total

73
92
165
144
150
294
94
81
175
68
82
150
784

Total

59

Age Groups in Years
≥15<50
≥50
263
113
376
459
222
681
218
92
310
221
133
354
1721

108
44
152
240
84
324
100
43
143
86
45
131
750

Total
444
249
693
843
456
1299
412
216
628
375
260
635
3255

The number of females was higher than the number of males in the study with 2,074
women (63.7%) and 1,181 men (36.3%). The femininity ratio (FR) was 1.76, being
higher in older people, from 15 to 94 than young people from 5 to 15; 2.18 and 0.94
respectively. This tendency also can be seen in age group by 5 years from 5 to 9 to 90 to
94. (Table 3).
Table 3
Distribution of the people studied by age group, gender and Femininity Ratio (FR).
Age Groups in years

Female

Male

Total

5-9
10-14
15-19
20-24
25-29
30-34
35-39
40-44
45-49
50-54
55-59
60-64
65-69
70-74
75-79
80-84
85-89
90-94
Total

176
203
197
184
188
191
150
140
111
144
136
76
78
52
23
14
8
3
2074

206
199
135
78
92
90
54
51
60
54
40
45
30
24
15
5
1
2
1181

382
402
332
262
280
281
204
191
171
198
176
121
108
76
38
19
9
5
3255

Femininity Ratio
(FR)
0.85
1.02
1.46
2.36
2.04
2.12
2.78
2.75
1.85
2.67
3.40
1.69
2.60
2.17
1.53
2.80
8.00
1.50
1.76

These femininity ratios by age groups were similar in the four barrios of Maracay,
and comparing with the total. (Table 4).
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Table 4
Distribution of Age Group, Gender and Femininity Ratio in the Four Neighborhoods in
the study. Maracay 2006-2008.
Age
Neighborhoods (Barrios) Group Female
23 de Enero
<15
73
≥15
371
Caña de Azúcar
<15
144
≥15
699
Cooperativa
<15
94
≥15
318
Piñonal
<15
68
≥15
307
The Four Neighborhoods
<15
379
≥15
1695
Total
2074

Male
92
157
150
306
81
135
82
178
405
776
1181

Total
165
528
294
1005
175
453
150
485
784
2471
3255

Femininity
Ratio
0.79
2.36
0.96
2.28
1.16
2.36
0.83
1.72
0.94
2.18
1.76

The study of the cohort began in September 2006 with 2,509 people. During the first
year of follow-up, until September 2007; 556 people were added in the cohort. In the
second year of the study, 190 people were added, from October 2007 to December 2008.
The people lost in the follow-up were 471 in the first year (15.4%) and 239 (8.6%) in
the second one. These people were lost in both groups: on the active surveillance of
febrile cases of dengue and in the bi-annual detection of specific IgG antibody antidengue. However, 178 people rejected, exclusively, to participate in the bi-annual blood
sample to detect specific IgG antibody anti-dengue so they kept in the active surveillance
of febrile cases of dengue, (66 people in the first year and 112 in the second one).
In the total period of two years 710 people (21.8%) were lost in the follow-up on active
surveillance and 888 (27.3%) in both the active surveillance and bi-annual IgG antidengue antibody detection.

61

Table 5.
Distribution of the people according to their type of permanency in the study. Maracay
2006-2008.
Group
of Age
and
sex

People
who
never
left the
Cohort
Group
I

< 15
> 15
Sub-Total
Females
Males
Sub-Total
Total

622
1745
2367
823
1544
2367
2367

People who
only left
the Bi-annual
blood sample
but not the
active
surveillance.
Group II
38
140
178
86
92
178
178

People who
Left and came
back to the
Cohort
Group III

People who
left the
cohort.
(Did not die)
Group IV

People
Total
Who Died
(Other
causes,
not
dengue)
Group V

9
21
30
12
18
30
30

115
544
659
247
412
659
659

0
21
21
13
8
21
21

(14.7%)
(22.0%)
(20.2%)
(20.9%)
(19.9%)
(20.2%)

784
2471
3255
1181
2074
3255

From these 710 people lost in the active surveillance, 21 died by causes different than
dengue (13 in the first year and 8 in the second one). 30 left and came back to the study
and 659 left definitely the study.
According to the type of permanence of the people in the study, there were five
groups: Type I, integrated by 2,367 (72.7%) people who never left the study. Type II, it
had 178 (5.5%) people who only left the Bi-annual blood sample component to detect
IgG specific antibody anti dengue virus but they did not leave the active surveillance
component. Type III, formed by 30 (0.9%) people who left and returned to the study
before it was over. Type IV, they were 659 (20.2%) people who left definitely the study
in both components (active surveillance and biannual blood sample). Type V: 21 (0.7%)
people who died during the period of the study. The Types I,II and III were always in the
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active surveillance part of the study and only the Type I was in the bi-annual blood
sample part of the study to detect IgG specific antibody anti dengue virus. (Table 5).
“23 de Enero” and “Piñonal” were the Barrios with the highest number of people lost
in the study, 25.1% and 23.3% respectively, and “Cana de Azúcar” and “La
Cooperativa” had 19.6% and 16.4% of people lost, respectively. The proportion of death
by no dengue cause was similar in the four barrios, being the fewer in “Piñonal” with
0.5% and higher in “La Cooperativa” with 0.8%.
The percentage of people lost in the follow-up was small in young people (5 to 15)
with 14.7% respect older people (>15%) with 22.9%. The male sex, lost in the study,
was little higher than female; 22.0% and 20.3% respectively. All people who died were
older than 15 (0.8%) and the proportion was higher in males than females (1.1% vs.
0.4%).
Table 5.
Distribution of the people according to their type of permanency in the study. By
neighborhoods, Maracay 2006-2008.
Neighborhoods
(Barrios)

People
who never
left
the
Cohort
Type I

23deEnero

468

People
who only
left the Biannual
blood
sample
Type II
37

People
who Left
and come
back
Type III

People who People
left
the who Died
cohort.
Type V
(Did not die)
Type IV

Total

14

169 (24.4%)

5 (0.7%)

693

Caña de
Azucar
Cooperativa

984

55

5

247 (19.0%)

8 (0.6%)

1299

474

42

9

98 (15.6%)

5 (0.8%)

628

Piñonal

441

44

2

145 (22.8%)

3 (0.5%)

635

Total

2367

178

30

659 (20.2%)

21 (0.7%)

3255
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Incidence Density
The people in the study (3,255) contributed with 1,914,496 person-days (p/d) during
the two years of follow-up. The period from Sep. 06, 2006 to Sep. 30, 2007 (2006-2007)
had 808,339 p/d and the period from Oct. 01, 2007 to Dec. 08, 2008 (2007-2008) had
1,106,157 p/d. Dividing the study period in nine trimesters, the first one had 132,396 p/d
and the last one 177,453. Every other trimester had values among 218,000 p/d and
239,000 p/d. In this study period were also considered the number of person days by
each month, with a total of 28 months. September 2006 had 528 p/d, October 2006 had
18,388 p/d and November 2006 had 41,566 p/d. From December 2006 until November
2008 all amounts of person-day were among values of 70,000 and 81,000. Finally,
December 2008 had 20,592 p/d.
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Figure 1 Incidence Density and Number of dengue cases by month, Maracay. 2006-2007

According to the kind of permanence in the cohort, the people from the Type I, who
never left the cohort, contributed with 1,634,162 p/d: 627,566 in the first year (20062007) and 1,006,596 in the second one (2007-2008). The people lost (Type IV) gave
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117,594 p/d in the period 2006-2007 and 14,438 in the period 2007-2008. Dead and
reincorporated people had a little impact in the number of person days. . (Table 7).
Children, 5 to 15, contributed with 475,764 p/d and adults (>15) added 1,438,732 p/d
in the study. Males and females between 5 and15 had similar number of person days,
243,438 and 232,326 respectively. However, adult females had 1,009,188 p/d versus
429,544 p/d of adult males. (Table 8).
Table 7.
Number of person/days (p/d) by type of permanency in the study and by month in two
years of follow-up. Maracay 2006-2008
2006-2007
Type I*

Oct06
334

Nov06
13549

Dic06
29997

Jan07
50719

Feb07
53754

Mar07
48552

Abr07
53754

May07
52500

Jun07
58720

July
07
64115

Ago07
67921

Sep07
67921

Type II

23

817

2041

4390

4898

4424

4898

4762

5038

5133

5394

5394

Type III

0

131

369

613

651

588

590

479

491

494

527

527

Type IV

163

3784

8871

15675

16685

14753

14229

10621

8770

6011

6076

6076

Type V

8

107

288

517

525

422

465

450

470

450

443

374

Total
Person/Days

528

18388

41566

71914

76513

68739

73936

68812

73489

76203

80361

80292

2007-2008
Type I

Oct07
65730

Nov07
67921

Dic07
65730

Jan08
69913

Feb08
71610

Mar08
66990

Abr08
69300

May08
71610

Jun08
71666

July
08
70769

Ago08
73377

Sep08
73377

Type II

5220

5394

5220

5463

5518

5162

5518

5340

5518

5340

5518

5518

Type III

510

499

526

307

186

174

186

162

244

597

682

682

Type IV

5880

5762

4639

1606

372

339

372

360

372

254

93

93

Type V

258

222

195

134

124

116

124

93

93

85

62

47

Total
Person/Days

77598

79798

76310

77423

77810

72781

75500

77565

77893

77045

79732

79717

2007-2008
Type I

Oct08
71010

Nov08
73377

Dic08
18936

Total
p/d
1634162

Type II

5340

5518

1424

129563

Type III

660

700

232

12587

Type IV

90

78

0

132032

Type V

30

31

0

6152

Total
Person/Days

77130

79704

20592

1914496

* Type I: People who never left the Cohort. Type II: People who only left the Bi-annual blood sample
Type III: People who Left and come back to the study. Type IV: People who left the cohort. (Did not die). Type V: People who died.
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The barrio “23 de Enero” had 381,295 p/d from 693 participants, “Cana de Azucar”
contributed with 780,521 p/d from 1,299 people. “La Cooperativa” added 389,825 p/d
with 628 people in the study and finally “Pinonal” had 362,855 p/d and 635 people in
follow-up.
Table 8.
Number of person/days (p/d) by neighborhoods, age group and gender Maracay 20062008.
Neighborhoods
(Barrios)

23deEnero
Caña de Azucar
La Cooperativa
Piñonal
Total

Children less than
15 years old
Females Males
38733
54286
91551
94697
61331
50747
40711
43708
232326
243438

Subtotal
93019
186248
112078
84419
475764

Adults equal and higher than 15
years old
Females Males
Subtotal
209081
79195
288276
416868
177405
594273
203811
73936
277747
179428
99008
278436
1009188 429544
1438732

Total

381295
780521
389825
362855
1914496

The crude incidence density of the cohort during two years was 3.24 by 100,000 p/d
(2.01 by 100,000 p/d adjusted by age group and gender of Maracay population): The first
year (from Sep 2006 to Sep 2007) the ID was 5.69 p/d and 1.45 p/d in the second year
(Oct. 2007 to Dec. 2008). The trimester with higher incidence density in both years of
study was from July 2007 to September 2007 with 8.81 p/d. All trimesters in the first year
had higher ID than second one. The months with higher ID were July 2007 (11.20 p/d)
and August 2007 (11.21 p/d) (Figure 1).
In two years of study (2006-2008), “Cana de Azucar” was the barrio with the highest
Incidence Density: 4.23 p/d, followed by “La Cooperativa”: 3.59 p/d. However, in the
2006-2007 period “La Cooperativa” had 7.92 p/d of Incidence Density and “Cana de
Azucar” had 6.67 p/d. In all Barrios, the ID was always higher in the first year of the
study; 2006-2007. (Figure 2).
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Table 9.
Number of cases, person days (p/d) and Incidence density (ID) distributed by
neighborhoods, gender and age groups, Maracay 2006-2008.
Neighborhoods
23 de Enero

Cana
de Azucar
Cooperativa

Pinonal

Total

Cases
p/d
ID
Cases
p/d
ID
Cases
p/d
ID
Cases
p/d
ID
Cases
p/d
ID

Males
<15
2
54286
3,68
7
94697
7,39
8
50747
15,76
1
43708
2,29
18
243438
7.39

Females
<15
4
38733
10,33
10
91551
10,92
2
61331
3,26
1
40711
2,46
17
232326
7.31

Total
<15
6
93019
6,45
17
186248
9,13
10
112078
8,92
2
84419
2,37
35
475764
7.36

Males
>15
1
79195
1,26
3
177405
1,69
2
73936
2,71
0
99008
0,00
6
429544
1.40

Females
>15
3
209081
1,43
13
416868
3,12
2
203811
0,98
3
179428
1,67
21
1009188
2.08

Total
>15
4
288276
1,39
16
594273
2,69
4
277747
1,80
3
278436
1,08
27
1438732
1.88

Total
10
381295
2,62
33
780521
4,23
14
389825
3,59
5
362855
1,38
62
1914496
3.24

The incidence density during the two years study was higher in infants from 5 to 15
years old with 7.36 p/d than adults equal and higher than 15 years old with 1.88 p/d. This
difference was in both years of the study, but it was much evident in 2006-2007. (Table
9). In the period 2006-2007 and in the four barrios the incidence densities were always
higher in infants but in 2008 in two barrios the Incidence density were a little higher in
two of the four barrios. (Piñonal and La Cooperativa) (Figure 2).
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Figure 2. Incidence Density of confirmed dengue cases by Neighborhoods, age group and
year of follow-up. Maracay 2006-2008

Relative Risk in Age Groups
In the two of years study (2006-2008), the Relative risk (RR) in confirmed infant cases
respect to adults was 3.92 (95% IC 2.38 – 6.48) being 4.77 (95% IC 2.66 – 8.54) in 20062007 and 2.52 (95% IC 0.91 – 6.94) in 2007-2008. According to gender, in females
between 5 to 15 the ID was 7.32 by 100,000 person-days and 2.08 in females higher than
15. RR 3.52 (95% IC 1.86 – 6.66) In males 5 to 15 the ID was 7.39 by 100,000 persondays and 1.40 by 100,000 person-days in males higher than 15. RR 5.28 (95% IC 2.10 –
13.33). In the period 2006 to 2007 the Relative Risk in females was 5.13 by 100,000
person-days; 15.01 by 100,000 p/d in females from 5 to 15 and 3.00 by 100,000 p/d in
older female. In the same period, the ID in male 5 to 15 was 14.37 by 100,000 p/d and
2.71 by 100,000 p/d in male older or equal than 15. In the period 2007-2008, the ID was
reduced similarly in both sex and age: 2.16 by 100,000 p/d in young women and 1.39 by
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100,000 p/d in the older ones and 2.74 by 100,000 p/d and 0.41 by 100,000 p/d in young
and older men respectively (Table 10).
Table 10
Relative Risk ID of age group and gender by years of the study.

Age Group
(Children/Adults)
Female
Male
Gender (female/male)
Children
Adults

2006-2008
RR
IC
3.92
2.38-6.48*

2006-2007
RR
IC
4.77
2.38-6.48*

2007-2008
RR
IC
2.52 0.92-6.94

3.52
5.29
0.86
0.99
1.22

5.00
5.30
0.76
1.04
1.11

1.55
6.72
1.20
0.79
3.41

1.86-6.66*
2.10-13.3*
0.51-143
0.51-1.92
0.49-2.52

2.35-10.64*
1.91-14.78*
0.42-1.37
0.50-2.19
0.39-3.10

0.41-5.86
0.75-60.11
0.42-3.46
0.18-3.52
0.43-27.23

* Significant Relative Risk.

During the two years study, the Incidence Density in female was 3.06 by 100,000
person-days and 3.56 by 100,000 persons-days in males: RR female/male: 0.86 (95% IC
0.51 – 1.43). In females <15 the ID was 7.32 by 100,000 person-days and 7.39 in males:
RR 0.99 (95% IC 0.51 – 1.92). In female >15 the ID was 2.08 versus 1.40 in women: RR
1.22 (95% IC 0.49 – 2.52).
Prevalence of antibody anti dengue virus and Incidence of infection by prospective seroprevalence of antibodies: IgM anti-antidengue antibody.
The first biannual sample (at the beginning of the study) was made in all the 3,255
participants in different times of the study, depending when they were included in the
cohort. Out of them, 75 (2.3%) were IgM positive, 21 children and 54 adults. In the
second biannual sample 2,622 people were tested and 86 were IgM positive (3.28%) 4
of them had been detected with dengue infection by the Active Surveillance few weeks
before (with a limit of 13 weeks), either by IgM or RT-PCR. In the third biannual sample
116 people were IgM positive and 11 were detected with dengue infection by active
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surveillance in a period from zero to 13 weeks before the biannual sample. 2,402 people
were participating in this third test so 105 (4.4%) were asymptomatic. In the fourth
biannual sample 69 people were IgM positive, only one of them had been detected by the
active surveillance system. It represented 3.24% of 2,129 people. The fifth and last
biannual sample had 61 IgM positive and two of them were detected previously by the
active surveillance system. 1,599 people were tested.
Bi-annual samples, Plaque Reduction Neutralization Test.
The Plaque Reduction Neutralization Test (PRNT) was applied in 2125 people; 65.3%
from all people in the cohort. Four samples from 1,684 people who began the study
cohort in 2006 and three samples from 441 people who began the study cohort in 2007.
In the first sample (S1) in both years of the cohort, the PRNT detected at least one of the
four anti DENV antibodies in 1,840 people (86.6%), it was negative in 283 (13.4%)
people and 2 participants were not tested in their S1. All the anti DENV antibodies were
detected either alone or in combination with other serotypes. Anti DENV-1 antibody was
positive in 1,573 (74%) people but only in 157 (7.4%) this antibody was found alone.
Anti DENV-1 and DENV-2 antibodies were positives simultaneously in 1,386 (65.2%)
people. Three anti DENV serotypes were positive in 401 people and anti DENV 1,
DENV-2 and DENV-3 antibodies were the most frequent combination, it occurred in 371
(92.5 %) people. The four antibodies were present in 31 (1.5 %) people. (Table 11).
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Table 11
Results of Plaque Reduction Neutralization Test in the first sample of people studied;
distributed by number of serotypes detected in each participant
.
Negatives and number of
Frequency
% of the
% of the total
Serotypes detected
subtotal
in each individual.
One Serotype
401
N/A
18.9
DENV-1
157
39.2
7.4
DENV-2
166
41.4
7.8
DENV-3
70
17.4
3.3
DENV-4
8
2.0
0.4
Two serotypes
DENV-1 DENV-2
DENV-1 DENV-3
DENV-2 DENV-3
DENV-1 DENV-4
DENV-2 DENV-4
DENV-3 DENV-4

Three Serotypes

1007
955
23
16
6
2
5

N/A
94.8
2.3
1.6
0.6
0.2
0.5

47.4
44.9
1.1
0.8
0.3
0.1
0.2

401

N/A
92.5
7.2
0.3

18.9
17.5
1.4
0.05

31

N/A

1.5

283
2
2125

N/A
N/A

13.3
0.1
100

DENV-1 DENV-2 DENV-3
DENV-1 DENV-2 DENV-4
DENV-1 DENV-3 DENV-4

Four Serotypes

371
29
1

DENV-1 DENV-2 DENV-3 DENV-4

Negatives
NR
Total

According to the age group, from 5 to 9 years old (y/o) interval had the less proportion
of positive antibodies in S1 with 127 children (47.39%), in the next group from 10 to 14
y/o, 202 children were positive (75.01%). The number of positives were increasing in
correspondence with the groups of higher age: 89.34% in the group from 15 to 19;
94.34% in the group from 20 to 24; in the group of 45 to 49, 99.12% were positive.
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Separating into two age groups: less than 15 (children) and higher than or equal to15
(adults), the proportion of negatives was significantly higher in children: 34.45 % versus
4.72 % in adults. This difference was consistent and significant (p value < 0.01) in the
two years when the people started the study (cohorts of 2006 and 2007). The proportion
of antibodies against serotype 1 and 2 were higher in people > 15; 85.45 % and 87.34%
versus 24.31% and 25.51 % in people < 15 respectively. On contrary, people <15 had
lightly higher proportion of serotypes 3 and 4, but this difference was not significant.
(Figure 3).
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86.7

38.3

79.6

46.2

85.45

40.22

DENV-2

88.9

39.6

80.9

45.5

87.34

34.26

DENV-3

25.8

24.9

18.1

27.3

24.31

25.51

DENV-4

3.9

4.5

1.3

6.1

3.40

5.96

Negatives

3.2

43

11

25.5

4.72

34.45

Figure 3 Percentage of people with antibodies according to serotype and negative results
distributed by age groups and years when they started the study. Maracay 2006 - 2008.

Figure 4 showed the most frequent results of the PRNT. DENV-1 and DENV-2 were
in four of the five first more frequent results, representing 70.6%, in contrast DENV-4
was in 3.95% of all possible results and DENV-3 in 24.45%.
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If we compare the prevalence of the three most frequent results in the PRNT, which
included DENV-1 – DENV-2, DENV-1 – DENV-2 –DENV-3 and negatives according
to age groups each 5 years, we can see how the proportions descend in negative results
with the age groups and ascend with the serotype positive results. (Figure 5).
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Figure 4 Plaque Reduction Neutralization Test in the first sample of 2,125 people sorted
by most frequent results. Maracay 2006- 2008.
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Figure 5 Percentage of the three most frequent results of PRNT in the first sample of
people in the study by age group. Maracay 2006 – 2008.

Thirty percent of the negative people in the first sample were positive either to one or
more than one serotype six months later in the second sample (S2). In the third sample
(S3), it was 29.6% of positives and 23.8 % in the last sample (S4). The sero conversion in
people with previous detection of anti anti-dengue antibody serotype 2 was the highest
percentage in the second sample with 58.1 %. In the third sample (S3) people with
previous anti anti-dengue antibody serotype 4 was the highest with 50.0 % and finally
anti anti-dengue antibody serotype 3 was the highest in the last sample with 34.1%.
(Figure 6). The same analysis but considering the people with negative results and the
most frequent positive results (DENV-1 DENV-2, DENV-1 DENV-2 DENV-3, and
DENV-1 DENV-2 DENV-4) showed the people with no antibody had the highest
percentage of sero-conversion in the second sample (S2): 30.1%. In the third sample, the
people with DENV-1 DENV-2 and DENV-1 DENV-2 DENV-4 combination in the
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second sample had the highest percentage of sero-conversion with 36.7 and 35.7
respectively. (Figure 7).
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Figure 6 PRNT, percentage of sero conversion according to results of the previous PRNT
in the second (S2), third (S3) and fourth (S4) samples. Maracay 2006 – 2008.
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Figure 7 PRNT, percentage of sero conversion according to the most frequent results of
the previous PRNT in the second (S2), third (S3) and fourth (S4) samples. Maracay 2006
– 2008.

When we compared the sero-conversion proportion of negative people with that
proportion of people with previous monotypic antibody detection in the three samples
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(S1, S2 and S3); the proportion of sero-conversion was always higher in the people with
monotypic antibody. These differences were statistically significant. The people with
multitypic antibodies detected had always less proportion of sero conversion respect to
either people negative or people with monotypic antibody. (Table 12).
Table 12
PRNT, percentage of sero conversion according to results of the previous PRNT in the
second (S2), third (S3) and fourth (S4) samples by monotypic and multitypic antibodies.
Maracay 2006 – 2008.
PRNT
Sample 3
% of SeroConversion

29,9
58,1
40,0
37,5

Positives
/ Number
of people
in
sample 3
45/133
39/89
10/46
5/10

174/955

22,0

DENV-1 **
DENV-2
DENV-3

10/371

DENV-1 **
DENV-2
DENV-4

Monotypic
Multitypic
Negatives

DENV-1 *
DENV-2 *
DENV-3 *
DENV-4 *
DENV-1 **
DENV-2

Positives
/ Number
of people
in
Sample 2
47/157
86/166
28/70
5/8

PRNT
Sample 2
% of SeroConversion

PRNT
Sample 4
% of SeroConversion

33,8
43,8
21,8
50,0

Positives
/ Number
of people
in
sample 4
20/86
12/46
15/29
1/8

319/894

35,7

13/4818

43,6

3,8

13/574

2,3

10/125

1,4

4/29

13,8

18/49

36,7

10/26

38,5

166/401
188/1355
86/283

41,4 ***
13,9 ***
30.1 ***

99/278
35,6 ***
350/1517 23,1 ***
58/156
29,6 ***

23,3
26,1
34,1
12,5

48/169
28,4 ***
158/1232 12,8 ***
29/122
23,8 ***

* Monotypic antibodies ** Multitypic antibodies
*** P value < 0.05

The Logistical Regression model with the new infection of dengue in the sample 3,
after the second six months of the study, as a dependent variable and previous infection in
time cero (the first sample at the beginning of the study) and sample 1 (S1) at the first six
months, age, sex, residence (neighborhoods), time of the beginning of the study (cohort
76

2006 or 2007), number of serotypes in time cero and sample 1 and interaction variables
between age and sex, residence and age, cohort and age and cohort and sex as a factors or
independent variables showed a significant (P value less than 0.05) relation with age, and
number of serotypes in the sample 1 (sample previous to the new infection). The
difference was significant between 2 and 3 serotype. In conclusion, younger people and
two anti dengue antibodies in blood sample were the most important factors to predict a
new infection of dengue by PRNT.
Active Surveillance and Laboratory Diagnostic of dengue
270 people with possible dengue infection were detected by the surveillance action in
the prospective study; all of them had fever either equal or higher than 38º Celsius, at the
moment of the evaluation. The blood samples were taken the same day of the
surveillance detection and that occurred between the first and the eighth day post onset of
the symptoms. 137 (50.74 %) were less than 15 year old and 156 (57.78 %) were female.
The neighborhood “Pinonal” had the highest percentage of people detected in the
surveillance with 10.39% (66 from 635 people) and “La Cooperativa” had the lowest one
with 5.25%. (Table 13).
The highest proportion of blood samples were taken in the second and third day with
37% and 28% respectively and 96.68 % of the samples were taken at the fifth day, or
less, after the onset of the symptoms. (Table 14).
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Table 13
Number of possible cases of dengue detected in the active surveillance, distributed by
Neighborhood and their population, age-group and gender. Maracay 2006 2008
Neighborhoods
(Barrios) and their
population.

Children less than
Adults equal and higher Total
15 years old
than 15 years old
(% of
F
M
Subtotal F
M
Subtotal population)

23deEnero
693
Caña de Azucar
1,299
Cooperativa
628
Piñonal
635
Total Population
3,255

12

13

25

14

7

21

46 (6.64)

25

31

56

49

18

67

123 (9.47)

5

17

22

9

4

13

35 (5.25)

20

14

34

22

10

32

66 (10.39)

62

75

137

94

39

133

270 (8.29)

Table14
Number of cases, percentage and cumulative percentage by day of detection in active
surveillance. Maracay, 2006 2008.
Day of detection and
blood sample

Number of
cases

%

Cumulative
%

1
2
3
4
5
6
7
8

18
101
77
44
21
5
2
2
270

6.67
37.41
28.52
16.30
7.78
1.85
0.74
0.74
100.00

6.67
44.08
72.60
88.90
96.68
98.53
99.27
100.00

The dengue infection was confirmed in 62 (22.96%) patients by RT-PCR. In
addition, probable dengue cases were estimated by detection of anti anti-dengue IgM
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antibody, with ELISA. For this test, two samples were taken: the first in the acute phase
and the second one in the convalescence phase of the disease. 34 (54.84%) confirmed
dengue cases were people less than 15 years old and 28 (45.16%) in older participants.
The four serotypes were in both age groups. DENV-1 was more detected in <15 people
and DENV-2 DENV-3 and DENV-4 in >15 people. (P value <0.01, Chi2 test). DENV-1
and DENV-2 were 67.74 % of the total confirmed dengue cases. (Table 15).

Table 15
Number and percentage of confirmed dengue cases by RT-PCR in the active
surveillance at four neighborhoods of Maracay, distributed by age-group
and serotype. Maracay, 2006 - 2008.
Serotype

Children less
than 15 years
old (%)

Adults equal and
higher than 15
years old (%)

Total

DENV-1

17
(50.00)
10
(29.41)
3
(8.82)
4
(11.76)
34

4
(14.29)
11
(39.29)
4
(14.29)
9
(32.14)
28

21
(33.87)
21
(33.87)
7
(11.29)
13
(20.97)
62

DENV-2
DENV-3
DENV-4
Total

Three of the four neighborhoods had all dengue serotypes; only “Pinonal” had only
three dengue serotypes. There were not significant differences among the proportion of
serotypes among neighborhoods. Figure 8.
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DENV-1

1

7

8

5

21

Figure 8. Percentage and number of dengue cases by serotypes detected in each
neighborhood. Maracay, 2006–2008

73.48% of the confirmed cases by RT-PCR were detected in the first three days after
onset of the symptoms and 24.19% in the days fourth and fifth. (Table 16). DENV-2 was
the most detected serotype in the first two days after onset of the symptoms with 44.44%
of 27 people with DENV detected in these two days. DENV-1 was the most detected
serotype in the third, fourth and fifth days with 42.42%. However, these differences were
not statistically significant. (p value > 0.05, Chi2 test). 50 (18.5%) patients were negative
the days fourth and fifth after onset of the symptoms.
In the acute period (the first to seventh days after onset the symptoms) of the 270
people, the IgM MAC ELISA test was positive in 29 patients and positive in 52 patients
during the convalescence period (30 days after onset of the symptoms). In the acute
period IgM was positive in 7 (12.5%) of the 62 Confirmed cases and positive in 23 (38.33
%) of 60 confirmed cases in the convalescence period. Six cases (10%) were positives in
both periods (Table 17).
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Table 16
Number and percentage of cases detected by active surveillance according to DENV
specific serotype identified by RT-PCR in each day after onset of the symptoms, Maracay
2006 – 2008.
Serotype
1
1

2
6

(4.76)

(28.57)

D1
D2

(33.33)

(19.05)

(14.29)

(0.00)

(0.00)

21
(100.00)

2

10

3

3

1

1

1

21

(9.52)

(47.62)

(14.29)

(14.29)

(4.76)

(4.76)

(4.76)

(100.00)

D3

0

1

4

0

2

0

0

7

(0.00)

(14.29)

(57.14)

(0.00)

(28.57)

(0.00)

(0.00)

(100.00)

D4

Total
Positives

Day of detection after onset of the symptoms.
Number of people detected and percentage (%).
3
4
5
6
7-8
7
4
3
0
0

1

6

4

2

0

0

0

13

(7.69)

(46.15)

(30.77)

(15.38)

(0.00)

(0.00)

(0.00)

(100.00)

1
(1.61)

1
(1.61)

(100.00)

4

23

18

9

6

(6.45)

(38.00)

(29.03)

(14.52)

(9.67)

Negatives

62

14

78

59

35

15

4

3

208

(6.73

(37.50)

(28.37)

(16.83)

(7.21)

(1.92)

(1.44)

(100.00)

18

101

77

44

21

(37.41)

(28.52

(16.30)

(7.77)

4
(1.48)

270

(6.66)

5
(1.85)

Total

(100.00)

Table 17
Number and percentage of patient results of IgM MAC ELISA test according to day of
detection by active surveillance. Maracay, 2006-2008.
IgM

Day of detection after onset of the symptoms
Number of people detected and percentage (%).

Total

1

2

3

4

5

6

7

8

IgM
+

2
(11.11)

1
(0.99)

8
(10.39)

6
(13.64)

9
(42.86)

3
(60.00)

0
(0.00)

0
(0.00)

29
(10.74)

IgM
-

16
(88.89)

100
(99.01)

69
(89.61)

38
(86.36)

12
(57.14)

2
(40.00)

2
(100.00)

2
(100.00)

241
(89.26)

Total

18
(100.00)

101
(100.00)

77
(100.00)

44
(100.00)

21
(100.00)

5
(100.00)

2
(100.00)

2
(100.00)

270
(100.00)

P value Chi 2 0.0001
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The IgM MAC ELISA test was positive in 11 of 196 (5.61%) people who were tested
in the first three days, and 18 of 70 (25.71%) were positives in those people who were
tested between day 4 and day 6. In one hand, from 29 patients with IgM positive in the
acute phase 7 (11.29%) were also RT-PCR positive. In the other hand, 23 of 50 (38.33 %)
people were IgM positive in convalescence period. (p value 0.09, Chi2 test). (Table 18).
Table 18
IgM MAC ELISA test in Acute and convalescence phase of the disease according to
results of RT-PCR. Maracay, 2006-2008.

RT-PCR +
RT-PCR -

Total

IgM+
in acute
phase

N

% IgM +
in acute
phase

IgM+
in conv.
phase.

N

% IgM +
in conv.
Phase

7
22
29

62
208
270

11.29
10.58
10.74

23
27
50

60
162
222

38.33
16.67
22.52

Based in the positives RT-PCR of 62 people in active surveillance, we compared the
dynamic of the virus infection by the specific serotype PRNT results, detecting those
congruent and logical results between both tests. We look for: 1. temporal congruency
between confirmed dengue case in active surveillance and new infection dengue case
detected in the biannual sample to PRNT. 2. Specific serotype congruency between
confirmed dengue case in active surveillance and PRNT results. From 62 confirmed cases
by active surveillance: five were not tested by PRNT, four were detected by active
surveillance after the last biannual sample was taken. Ten PRNT results were incongruent
with confirmed dengue cases in active surveillance. 43 had temporal infection
congruency between active surveillance and PRNT biannual test, and 35 out of them had
also specific serotype congruency. Five of ten cases without congruency between RT82

PCR and PRNT were sero-negatives by neutralization, in three cases they were DENV-4
and DENV-3 in two, it does not happen with DENV-1 and DENV-2. Table 19.

Table 19
Congruency between confirmed dengue cases detected in Active Surveillance
and results of PRNT in biannual samples. Maracay, 2006-2008.
Number

%

Not tested by PRNT

5

8.1

Detected by Act. Surveillance after
last biannual sample. PRNT.

4

6.5

Neither temporal nor serotype infection
congruency.

10

16.1

Temporal Infection Congruency
Between AS and PRNT. *
Total Confirmed Dengue cases by AS

43

69.3

62

100.0
AS:

Active Surveillance
* 35 out of 43 confirmed cases were also congruent with the serotype reported by PRNT.

From the 35 confirmed dengue cases by active surveillance congruent with serotype
specific PRNT, DENV-1 has the best congruency with 88 % (15/17), DENV-3 has 78 %
(7/9), and DENV-2 69 % (11/16). DENV-4 has the lower proportion of congruency with
17 % (2/12).
The relation between primary and secondary infection detected by PRNT was
described with the IgM MAC ELISA test results of 62 confirmed dengue cases in active
surveillance, looking for any association between them. From 62 confirmed cases by RTPCR, 23 had IgM antibody sero-conversion, 39 had not IgM antibody sero-conversion in
either acute or convalescence phase of the disease. We compared the primary and
secondary infection in the 62 people by PRNT with both kinds of IgM MAC ELISA
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results. From 23 confirmed dengue cases who sero-converted, 61,1 % were primary
infection according to PRNT and from 39 confirmed dengue cases who did not seroconvert, 15,4 % were primary infection by PRNT. This difference was statistically
significant. Chi square p value < 0.0006.
Active Surveillance and clinical manifestation.
In the two years of study, 270 people were detected with fever and classified as
probable dengue fever by active surveillance, 62 were confirmed by RT-PCR. Headache
was the most frequent symptom, being referred by 94.9% of the people. Body pain,
shiver, ocular pain and joint pain were also referred for more than 50% of the people.
These percentages were affected significantly in the symptoms body pain, ocular pain,
joint pain and abdominal pain depending on the age-group of the people. (Table 20).
Table 20
Number and percentage of people with symptoms of dengue detected in the active
surveillance. Maracay, 2006-2008.

Symptoms
Headache
Body pain
Shivers
Ocular pain
Joint pain
Nauseas – Vomits
Abdominal Pain
Asthenia
Rash
Hyporeflexia
Tourniquet Test

Petechia

Number of
people with
symptoms.
256
206
196
186
159
128
108
93
66
62
21
11

%
N=270
94.82
76.30
72.59
68.89
58.89
47.41
40.00
34.44
24.44
22.96
7.78
4.01

% in patients
<15
N=137
92.70
65.69
68.61
61.31
45.99
46.72
32.85
35.04
25.55
21.17
8.03
2.19

% in patients
>15
N=133
96.99
87.22
76.69
76.69
72.18
48.12
47.37
33.84
23.31
24.81
7.52
6.02

Chi2
P value
NS
S
NS
S
S
NS
S
NS
NS
NS
NS
NS

When we compared the frequency of symptoms according to the dengue disease
confirmation by RT-PCR, headache was present in 96.9% of confirmed cases and 94.2 %
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in no confirmed cases. It difference was not significant (NS) statistically with a
probability value (p) higher than 0.05 (> 0.05). Ocular pain was showed by 68.89% of
the people; 79.03% in confirmed cases and 67.3% in no confirmed cases. It difference
was significant (S). Rash also had a significant difference between confirmed and non
confirmed cases with 37.10% and 20.67 % respectively. Body pain was positive in 75%
of the people but the difference between confirmed and no confirmed case was NS.
Similarly, shiver was referred by 71% of the people and the difference, between of
percentage of confirmed and no confirmed cases, was NS. In confirmed cases, joint pain,
abdominal pain, asthenia and nauseas were positive in 54.84, 46.77%, 30.65% and
53.23% respectively, without any significant difference with non confirmed cases. The
percentage of petechias and tourniquet test were always referred by less than 10 % of the
patients and there are no significant differences between confirmed cases and no
confirmed cases. (Table 21).
Table 21
Percentage of people with symptoms of dengue detected in the active surveillance by
confirmed and non confirmed dengue cases. Maracay, 2006- 2008.

Symptoms
Headache
Body pain
Shivers
Ocular pain
Joint pain
Nauseas and vomits
Abdominal Pain
Asthenia
Rash
Hyporeflexia
Tourniquet test
Petechia

% of people
with
symptoms.
Totals.
94.82
76.30
72.59
68.89
58.89
47.41
40.00
34.44
24.44
22.96
7.78
4.01

% Confirmed
Cases of
dengue.
N=62
96.77
72.58
74.19
79.03
54.84
53.23
46.77
30.65
37.10
22.58
9.68
8.02
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% Non Confirmed
cases of dengue
N=208
94.23
77.40
72.12
65.87
60.10
45.67
37.98
35.58
20.67
23.08
7.21
2.89

Chi2.
P value
NS
NS
NS
S
NS
NS
NS
NS
S
NS
NS
NS

Table 22 shows the results of a Logistic regression to estimate which symptoms could
be associated with dengue confirmed cases. It was adjusted by age-group, gender and
residency. Rash and ocular pain were associated with confirmed dengue.

Table 22
Symptoms associated with confirmed dengue cases, applying Logistic Regression
Maracay 2006 – 2008.
Variables
Age-group
Gender
Age-group * gender (M/F)
Neighborhood (2/1)
Neighborhood (3/1)
Neighborhood (4/1)
Asthenia
Abdominal Pain
Joint Pain
Headache
Body Pain
Hyporeflexia
Shiver
Nauseas Vomits
Tourniquet Test
Petechia
Ocular Pain
Rash
CONSTANT

Odds
Ratio
0,6091
0,4507
1,2688
1,9177
2,9112
0,2838
0,5765
1,3865
0,8475
1,1204
0,5717
1,0686
1,0694
1,2743
1,7111
1,8569
2,2507
2,1038
*

95% C.I.
0,262
0,0596
0,3277
0,801
0,9992
0,0787
0,2771
0,6888
0,3657
0,206
0,2257
0,4727
0,5001
0,6555
0,4105
0,3645
1,0035
1,0146
*

1,4159
3,4084
4,9124
4,5908
8,4818
1,0232
1,1993
2,7907
1,9641
6,0943
1,4481
2,4157
2,2867
2,4772
7,1333
9,4607
5,0481
4,3623
*

ZStatistic
-1,152
-0,7721
0,3447
1,4619
1,9585
-1,9249
-1,4736
0,9155
-0,3857
0,1316
-1,1791
0,1595
0,1729
0,7147
0,7374
0,745
1,9684
1,9989
-1,0243

P-Value
0,2493
0,4401
0,7303
0,1438
0,0502
0,0542
0,1406
0,3599
0,6997
0,8953
0,2383
0,8733
0,8627
0,4748
0,4609
0,4563
0,049 *
0,0456 *
0,3057

Note: * Significant p value.

From the people detected in the active surveillance, a sub sample of patients was
invited to participate in a special group of follow up. Several blood samples in the acute
and one in convalescence phase of the disease were obtained to see the dynamic of some
hematologic and serologic changes in those patients confirmed with dengue. From 270
people only 50 accepted to participate and out of them 17 were RT-PCR positive.
Hemoglobin, hematocrit, platelets, white blood cells, lymphocytes and neutrophils in the
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first sample were compared in confirmed and non confirmed dengue cases (Table 23). In
addition, only in the confirmed cases the hematologic and serologic indicators were
repeated at least three times in the acute phase of the disease Platelets and white blood
cells showed significant changes in that short period; both decrease in the second sample
and increase in the third one. (Table 24). Platelets and white blood cells also had been
less than values in non confirmed cases of dengue.
Table 23
Hematologic indicators of confirmed and non confirmed dengue cases at the moment of
the detection by the active surveillance. Maracay 2006 2008.

Hematologic
Indicator
Hemoglobin
Hematocrit
Platelets
White blood cells
Lymphocytes
Neutrophils

Confirmed
Cases N=17
Means
13.28
41.67
179 (51.4)
5.51
39.8
57.6

Non Confirmed
Cases N=33
Means
13.03
40.18
188,8 (51.7)
7.39
40.93
57.5

T test2.
P value
NS
NS
NS
S
NS
NS

Table 24
Hematologic indicators of 17 confirmed cases in three consecutives blood samples in
different days of acute phase of dengue disease. Maracay 2006 2008.

Hematologic
Indicator

Sample 1

Sample 2

Sample 3

Hemoglobin
Hematocrit
Platelets
White blood cells
Lymphocytes
Neutrophils

13.28 (1.59)
41.67 (5,91)
176 (51.4)
5.51 (2.21)
39.81( 13.6)
57.6 (14.9)

13.26 (1.30)
41.26 (4.75)
165 (46.1)
4.73 (2.05)
49.6 (13.7)
46.4 (16.7)

13.5(1.43)
41.34 (4.67)
188 (70.3)
5.00 (1.57)
55.29 (14.4)
41.8 (13.6)
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T paired test
between S2-S1
and S3-S2
P value
NS
NS
S
S
NS
NS

IgM MAC ELISA test was positive in 3 of 17 patients at the moment of their detection
by the active surveillance. The average of days after onset of the symptoms to take the
blood sample was 2.65 in the first day, 3.29 in the second day, and 3.88, 5.0, and 6.7 in
the third, fourth and fifth day respectively. All convalesce sample were obtained between
31 and 47 days after the onset of the symptoms. Four sero-conversions occurred in the
third, fourth and fifth samples and one negative patient in the acute phase converted in
positive in the convalescence sample. Finally, 8 (47%) patients never showed seroconversion in the period of acute and convalescence phase of the dengue disease and four
out of them were RT-PCR positive to DENV-4. (Table 25).

Comparing passive surveillance from regular system with
active surveillance in this study.
For all 270 people in the two years of the study, 76 (28.1%) were confirmed with
dengue disease by RT-PCR and IgM positive in sero-converted convalescence sample; 23
(8.5%) probable dengue cases and 171 (63.3%) negative cases were also identified.
Proportion of confirmed dengue cases was similar by age group, gender, days after the
onset of the symptoms, and clinical presentation. Proportion of probable cases was higher
in those people who were tested four or more days after onset of the symptoms (pvalue <
0.001) Figure 9.
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Table 25
Serological conversion to IgM anti-dengue antibody in 17 confirmed dengue cases in the
acute phase of the disease. Maracay 2006 2008.

Patient

Age

Sex

DV

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17

20
5
16
21
22
10
15
26
32
10
15
31
11
18
19
9
15

F
M
F
F
F
F
M
F
F
M
M
F
M
F
M
F
M

D1
D1
D1
D1
D2
D2
D2
D2
D2
D3
D3
D3
D4
D4
D4
D4
D4

First
Sample
DAOS
2
3
3
3
1
2
2
2
3
1
5
5
2
2
2
3
4

IgM1

+
+
+
-

Second
Sample
DAOS
3
/
4
4
2
3
3
3
4
2
/
/
3
3
3
4
5

IgM2

/
/
/
/
-

Third
Sample
DAOS
4
5
/
5
3
3
/
4
/
3
/
/
4
/
/
/
/

IgM3

+
/
+
/
/
/
/
/
/
/
/
/

onset of the symptoms.
DV: Dengue Virus serotype.
/ : No made
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Fourth
Sample
DAOS
5
/
/
6
/
/
5
5
/
4
/
/
5
/
/
/
/

IgM4

/
/
/
/
/
/
/
+
/
/
/
/

Fifth
Sample
DAOS
8
7
6
9
5
6
8
9
6
6
7
7
7
5
5
6
7

IgM5

/
/
/
+
/
/
/
-

Sixth
Sample
DAOS
44
37
35
45
33
35
45
38
31
32
39
37
38
36
46
42
47

IgM6

+
+
+
+
+
+
+
-

Note: DAOS:
Days after

100%

80%

60%

40%

20%

0%

<15

>=15

Female

Age group

Males

<4 days

Gender

>=4 days HDF

DAOS

DF

Clinical
Manifestation

Total

Negatives

79

93

103

69

137

35

1

171

172

Probable

15

7

8

14

7

15

3

19

22

Confirmed

43

33

45

31

52

24

3

73

76

Figure 9 Dengue case definitions by age group, gender, days after the onset of the
symptoms and clinical presentation in the people detected in the active surveillance.
Maracay, 2006-2008.

2007 was a national dengue epidemic year, for that reason we compared this specific
year with our data. We had 47 confirmed dengue cases in 2007 and the Cumulative
Incidence was 1,873 per 100,000 populations. The months with highest CI were July,
November and August. From January to May can see a reduction in the number of cases
which is zero in May. Figure 10.
Figure 11 shows the index of pluviosity by months in Venezuela compared with
the cumulative incidence of dengue disease by months per 100,000 populations. The
months with higher pluviosity are almost coincident with the months with where the
cumulative incidence is greater.
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Cases per 100,000 Populations
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Figure 10 Cumulative Incidence by months per 100,000 populations in the study cohort,
during 2007. Maracay, 2006-2008.
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Figure 11. Cumulative incidences of dengue disease by months per 100,000 populations
in the study cohort and pluviosity in centimeters during 2007 Maracay, 2006-2008.
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The 2007 cumulative incidence of dengue disease in the cohort study (1,873 per
100,000 populations) was higher than cumulative incidence in the state of Aragua (496
per 100,000 populations) in the same year. Analyzing the cumulative incidence per
months in 2007, except May in all months the cumulative incidence of dengue of the

Cumulative Incidence per 100,000 populations

cohort study was higher than the state of Aragua. Figure 12.
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"Barrios" by Regular Surveillance
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29.8

17.3

35.6

56.8

91.4

46.2

75

79.8

35.6

Aragua State

29.8

22.1

17.5

13.1

18.2

30.6

54.1

76.4

60.5

70.3

64.5

38.8

Figure 12. Cumulative incidence of dengue disease by month. Ccomparison between
study cohort and regular surveillance in the same barrios of the study and in the state of
Aragua in 2007. Maracay 2006-2008

Figure 13 shows the endemic levels of dengue in Venezuela and the cumulative
incidence of dengue disease in 2005, 2006 and 2007. The cumulative incidence of
dengue in 2005 increased in the rainy months from June to September but this CI never
passed the limit from endemic to epidemic (up to one standard deviation of the average)
instead in 2006 the CI became epidemic in September and it was maintained in epidemic
phase from October 2006 until December 2007.
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Figure 13. Endemic levels of dengue in Venezuela and the cumulative incidence of
dengue disease in Venezuela in 2005, 2006 and 2007. Maracay, 2006–2008.
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CHAPTER FIVE: DISCUSSION

In general terms the center of this study was to identify in a sample of one dengue
disease endemic population those aspects that cannot be seen and understood in a regular
public health surveillance system. The goal in a traditional passive surveillance is to
detect a non expected number of cases in a specific period of time, assuming that any
frequency of sick people can be correlated with the dynamic of the infection disease.
Many times, the high number of detected disease cases cannot be equated to infectious
disease intensity; the real strength of the infection could be masked if it is considered as a
lineal relation. Silent or unapparent cases might not be important in other viral infections;
on contrary; it could be a way to get immunity. However, dengue disease does not follow
the same pattern. A previous benign infection could be a risk to get a secondary severe
and sometimes fatal disease. In addition, people that are not recognized as sick patients,
can be a source of potential transmission without a preventive action to reduce it.
In this study design one of the main ideas was to know exactly how many people were
clinically sick. Visiting their houses three times a week was the way to avoid the nonregistration of febrile people who could not have felt sick enough to go to the health
service which is inserted in a traditional passive surveillance system. Additionally, this
permanent contact with the people permitted us to know those healthy people who have
had dengue antibody sero-conversion during the study; people whom neither active nor
passive surveillance would have been able to detect as infected ones.
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Even considering these previous aspects, it is important to discuss that active
surveillance is designed not only to call or visit the place looking for cases, but also it
could include special monitoring systems in specific samples from the population, of
course, it always depends on the characteristics of the disease. Hypothetically in a Public
Health Service, biannual sample to sero-prevalence test combined with active
surveillance in a little sample of people could be a monitoring strategy to estimate, with a
reasonable confidence level, the silent dynamic of the infection in the population.
In one sense our results support the idea that new monitoring methods have to be
implemented, beyond to the traditional and passive strategies to respond against dengue
disease. With some exceptions most of the developing countries where dengue is a real
problem, these new strategies are needed. The focus of this discussion was oriented to
relate analysis results with a hypothetic Public Health Surveillance System. In another
sense, our results can be discussed in particular terms, and each part of the study can add
information to the knowledge of dengue disease.
In this study the frequency of dengue disease and dengue infection were measured by
two ways. On the one hand, the disease was directly estimated by the incidence of the
dengue cases in the active surveillance and prospective design. Moreover, the infection
was indirectly estimated by the sero-prevalence of the antibodies against dengue virus,
which were obtained in fixed biannual blood samples. Two kinds of antibodies were
tested: IgM and IgG. anti-dengue antibodies. IgM MAC ELISA test detected antibodies
which are circulating in blood around three months after dengue infection, consequently
IgM could not have been detected in a half of the total people with IgM sero-conversion;
however, it could be a good indicator of silent infection. IgG anti dengue antibody was
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measured by Plaque Reduction Neutralization Test. With this technique IgG anti dengue
antibody can be detected 50 years after infection. However, PRNT is mainly a sensitive
procedure to detect dengue primary infection been also a perfect test to identify
serotypes.
The present project is one of the few prospective dengue studies where the people were
followed-up by door to door visits three times a week, asking for febrile cases. In the
bibliographic review we checked 75 articles in PubMed of NCBI, using the key words:
Dengue, prospective, incidence and prevalence to look for dengue prospective studies.
We used the following descriptor: (Dengue and prospective) or (dengue and incidence) or
(dengue and prevalence). The major numbers of prospective studies were made in
community schools, being the children absence to class the alarm to investigate the cause.
Other prospective studies were based in the use of health care services; when the people
in the follow-up felt sick, they should have gone there. In another prospective adult
studies, the workplace was the center of the follow-up. According to our review, none of
the papers evaluated were made with a strategy of house visits. Our study, with three
visits a week, gave us direct information about the patients and verified when exactly the
onset of the symptoms occurred.
In this study, the general incidence density in two years was 3.24 per 100,000 p/d. Few
studies have reported Incidence Rate as incidence indicator; most of them have used
Cumulative Incidence, being difficult to do a direct comparison with our results. Porter et
al,. in 2005, have been one of the authors who reported Incidence Density. However,
their study was made in adults and the ID was expressed in person/years (p/y). Eighteen
cases per 1,000 p/y was the ID in 2,536 workers from two textile factories in Bandung,
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Indonesia in two years study from 2000 to 2002. Expressed in person/days, that means
an ID of 4.9 per 100,000 person/days higher than 1.9 p/d adults ID in our study. In
dengue, this kind of difference could express two contrary situations. In one sense, if both
places had the same structure of viral transmissibility with similar inter-epidemic periods,
similar sero-prevalence of anti-dengue antibody by age groups, and similar number of
serotypes circulating; probably, we could say that either for some unknown reason (like
human genetic variation, or virulence, or environmental factors) or for specific risk in the
work place (textile factory) the adults ID in Bandung is grater than adults ID in Maracay.
In another sense, if each city has different endemic or hyperendemic history and the seroprevalence of antibodies by age groups are dissimilar, the situation analysis would be also
different. Comparing the entire population cumulative incidence in similar periods in
both countries where these cities exist; we can see that in Venezuela (where Maracay city
is) historically has had four o five times more annual CI than Indonesia, (where Bandung
city is): 143 and 26 per 100,000 populations respectively (six years average from 2000 to
2005). The same conclusion can be made comparing cumulative incidence reported
between Bandung and Maracay. From 1995 to 1998, Bandung had CI of 44, 54.7 and
31.7 per 100,000 populations and Maracay, from 1996 to 1998, had CI of 73, 155 and
157 per 100,000 populations, respectively. According to these studies, in Maracay city
respect to Bandung city, adults would have less susceptibility to dengue disease, being a
place where the disease is probably, in terms of risk, a higher problem of public health.
(Porter et al 2005), (Barrera et al 2002).
Saddiqui et al in Karachi (Pakistan) reported an Incidence Rate of 0.5 cases per
100,000 person/days in children in a 30 months study period. They obtained incidence

97

rate of 0.4 cases per 100,000 person/days in age group from 5 to 10 year old and 1.6
cases per 100,000 person/days in age group from 11 to 15 year old. This values are low
compared with the ID of 7.4 cases by 100,000 p/d found in our study in two years of
study. This big difference could be explained because Pakistan has begun their dengue
high epidemics in 1994 to 1996, and the second big epidemic occurred in 2006; 4 years
after the study of Siddiqui et al was made. (Siddiqui et al 2009). In contrast, Venezuela
has had several big epidemics from 1989 until 2008 when our study was completed.
The difference between the study in Bandung and Karachi respect to our study is that
children in endemic areas are always the target of dengue infection and dengue disease,
making it easier to compare the Karachi city children study with our study. There are
logical exceptions like Cuban dengue disease epidemic in 1997, where adults were
almost exclusively affected, even though the dengue infection should have affected all
population. (Guzman 2005).
Prospective incidence and sero-prevalence studies should always consider children and
adult people in their samples, to have a better perception about the viral dynamic in the
people. In a monitoring surveillance of sample or sentinel population it would be
indispensable.
Although most of the prospective studies of dengue have reported cumulative
incidence instead of incidence rate, when we assume that population is stable in the time
(in size and age distribution) the person/time can be calculated multiplying the size of the
disease free population by the actual duration of follow-up (Morgenstern, 1980), even
considering that is difficult because of withdrawals from the study cohort.
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Acording to the last paragraph, we estimated the differences and similarities between
our results and the other worldwide incidence studies.
Historically, two of the first prospective dengue studies were completed in Thailand in
the 80’s, both based in the 1980 epidemic. One of them was done in Rayong city
(Sangkawibha et al 1984) and the other in Bangkok city (Burke et al 1988). However,
disease incidence was reported only in the Bangkok study; it was completed in an exact
period of 7 months and based in the children school absenteeism. Due to the finalization
of the study by all the children, a close approximation to person time can be made. In
seven months, the study reported 5.6 % of incidence, around 26 cases per 100,000
person/days clearly higher to 7.4 cases per 100,000 p/d incidence density that we found in
Maracay. The importance to compare our study with the Bangkok study, in Thailand, was
because this city has reported dengue cases from 1958, and Thailand with Philippines
were the first countries where DHF outbreaks occurred, sharing with Venezuela
hyperendemicity, age population structure, weather conditions, similar dengue
cumulative incidence, and incidence of DHF. In some aspects of dengue, Thailand is to
South East Asia, as Venezuela is to Latin America.
Eighteen years after Burke’s study, Endy et al. repeated a similar study in schools
situated in a district close to Bangkok. This time, the incidence of the dengue disease was
3.6% in 1998, approximately an Incidence Density of 9.9 cases per 100,000 p/d, 3.3%
in1999, ID :9.0 cases per 100,000 p/d. and 0.8% in 2000, ID:2.2 cases per 100,000 p/d.
The overall incidence in the three years study was 2.7% with an estimated ID of 7.4 cases
per 100,000 p/d, the same values of our results of 7.4 cases per 100,000 p/d. This study
was probably more accurate than Burke’s study 18 years before, the dengue disease and
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dengue infection were better defined. Contrary to the other study of Bangkok, it was also
designed to evaluate any children with one or more days of absence. One advantage in
our study, in Maracay, was that we were usually able to make the medical evolution the
first or second day after the onset of the symptom, and that day was exactly registered.
We will get back to this point in the discussion of the clinical part of the study. (Endy et
al, 2002).
In the Americas few studies of incidence of dengue disease have been made,
Balsameda et al in Nicaragua reported an annual incidence of 8.5 cases per 1,000
schoolchildren in the first year of follow-up, and 8.3 per 1,000 schoolchildren in the
second one; assuming the study did not have any lost, it means approximately 2.33 and
2.27 cases per 100,000 p/d respectively. (Balmaseda et al. 2006)
One limitation in many of the previous discussed studies is that they could not measure
the incidence of the disease associated to age groups (children and adults), because those
studies have been made either in children (usually in schools) or in adults. Working
directly in the community permitted us to evaluate simultaneously the incidence in both
groups and estimate the risk association. Its Relative Risk was 3.92 in children respect to
adults, in the two years of the study; however, this risk was significant only the first year
of follow-up, when the big Venezuelan dengue epidemic was occurring in 2007. This RR
was consistent in females and males, in the overall two years study. This result could
indicate that in endemic period the risk between children and adults tends to be similar,
being children clearly affected in epidemic periods.
The incidence of dengue disease was close related with two external factors, the year
of the study and the rainy months. The incidence density in the first year study (2007)

100

was affected by the second highest epidemic in Venezuela in the last twenty years. The
Venezuelan cumulative incidence in 2007 was 304 per 100,000 populations; since 2002
no annual CI in Venezuela was higher than 160 per 100,000 populations. In Aragua
state, where this study was made, the number of dengue cases and the cumulative
incidence in 2007 has been the highest in the last twenty years. The other factor
associated with the incidence density was the rainy months. The months with highest
pluviosity: July, August and September were the months with the highest number of
dengue cases. This pattern was similar to the 2007 national and regional reports of
dengue cases. Even though, this result was less evident in 2008; dengue cases were
reported in the first months of raining (May and June), without dengue cases reported in
the months with less precipitations (January, February, March and April).This study with
a cohort of 3,255 people in four neighborhoods of Maracay reflected the national and
regional epidemic and how the rising of dengue cases are related with the rainy period
and the vector activity.
The incidence of the dengue disease has another advantage; it is the best way to
identify specific serotypes in areas of hyperendemicity. Plaque Reduction Neutralization
Test is the best test to estimate specific serotype in primary dengue infection, but it is not
the same situation in secondary and tertiary ones.
According to our results, we could not establish different spatial distribution of the
serotypes among the four barrios in Maracay city. Even though, these neighborhoods are
separated by at least one mile among them. Except “Pinonal” which had serotypes of
DENV-1, DENV-2 and DENV-3, the other neighborhood had the four serotypes. Endy et
al found specific serotypes as a focus of transmission in their prospective school based
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study, giving to schools and community similar role in the dengue transmission. (Endy et
al 2002). However, Mammen et al. studying spatial and temporal clustering virus
transmission found that community was more important than schools as a source of the
dengue infection transmissibility. (Mammen et al, 2008).
The proportion of DENV-1 serotype, into all children confirmed dengue cases, was
significantly higher than that proportion in adults. DENV-2 and DENV-3 proportions
were similar in children and adults, DENV-4 proportion was higher in adults but this
difference was not significant. Long history of exposure to endemic infection of dengue
can explain in adults the low proportion of DENV-1 which has been reported in the last
20 years in Venezuela. Similar proportion of DENV-3 in children and adults can be
explained because this serotype was hardly introduced in Venezuela in 2001 and
simultaneously many children and adults were infected. We could have expected with
DENV-2 a similar behavior to DENV-1, due to long time adult exposition to that
serotype.
As well incidence of dengue disease is a good indicator of imminent public health
problems like epidemics; incidence of dengue infection is the way to know how the
dynamic of the virus is and probably the way to predict disease events in the close future.
The sero-prevalence of IgM anti-dengue antibody in the first biannual sample was
2.3%, it could be considered low, thinking in a hyperendemic population with high rate
of infection. However, Gluber in 1998 reported that IgM titers in primary infection are
significantly higher than in secondary infections (Gluber, 1998). Then, it is possible to
deduce the less sensitivity of IgM CAPTURE ELISA detecting acute infections in
population (like ours) with high prevalence of secondary and tertiary infections. Besides,
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the lifetime of IgM antibody in people infected is around three months, and people
infected before that time would not be detected. 2.3 % or little more percentage, even in
a three months prevalence period, could indicate a high number of people who were
silently infected. In this study, that was impossible to know in the first biannual sample
but in a second biannual sample we were in capacity to know exactly which people had
been symptomatic and who had not, because they have been identified in the active
surveillance. In this context, the IgM sero-prevalence in the second biannual sample was
3.28%, 86 positive people in 2,622 populations tested. Out of them, only 4 people were
detected with fever in the active surveillance design, indicating that 84 (95 %) people
were probably asymptomatic or lightly symptomatic dengue cases. In the third biannual
sample, 116 people were IgM positive and 11 (9.5 %) out of them had been detected in
the active surveillance, a higher amount of people. In the fourth and fifth biannual sample
the percentage of possible asymptomatic people were 98 % and 97 % respectively out of
all positives IgM.
Sero-prevalence IgM test surveys in a sample population could be a quick and relative
low cost way to estimate the proportion of unapparent dengue infection. However,
reducing from 6 to 3 months period inter sero-prevalence samples would be a best way to
adapt this strategy to the immunological dynamic of IgM antibodies.
Any advantage that could have IgM MAC ELISA test will never have the accuracy of
PRNT to detect dengue infection and dengue specific serotype. Even though this test is
also affected by secondary infections reducing its capacity to identify specific dengue
serotype in samples from infected people with multiple dengue serotypes, PRNT
continues being the main test to detect dengue virus.
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We tested 2,125 people with PRNT, 65.3 % of the complete cohort. It was a significant
amount, thinking in this laborious and time consuming test. The overall sero-prevalence
of anti-dengue IgG antibodies was 86% in the first biannual survey, 65.6 % in children
less than 15 and 95.3% in adults. 66 % were positive to two or more dengue serotypes.
Negatives results were found in 283 (13%) people where 34.5% were children and 4.7%
adults. In Salvador city, Brazil, Texeira at al reported one of the few studies where they
are considering sero-prevalence simultaneously in children and adults. They showed
overall seroprevalence of 68.7%, 76.1% in adults and 57.4% in children. Similar to our
study, Salvador is a complex city with poor areas and socio economic variations.
However, its comparative lower seroprevalence could be explained because this study
was made in 1998 – 1999 when Brazil was not yet in its worst period of epidemic after
2001.(Texeira etal, 2002). Contrary to Texeira study but close to ours, Balsameda in
Nicaragua has showed seroprevalence in children of 91% from 75% at age 4 to 100% at
age 16. Historically, dengue epidemics in Nicaragua are similar to Venezuela and could
explain the closer dynamic of the virus in both countries. (Balmaseda et al, 2006). In
Veracruz, Mexico 2003, Navarrete et al found IgG dengue antibody sero-prevalence of
79.6% in 500 samples from all age, reporting an increase of prevalence from 17 % at 1
year old to 94 % in people equal or higher than 65 years old. Interestingly, seroprevalence in Texas Mexico-border, the authors reported prevalence of 40 % in
Brownsville and 80 % in Matamoros, increasing the percentage according to age stratus.
In the Maracay city, Comach et al in 2001 found a prevalence of 51 % in
schoolchildren, even though this study was made in the same city to our study, this lower
sero prevalence could be a main specific focus of dengue antibody prevalence and
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transmission and not necessarily antibody prevalence in geographic communities.
Mammen et al is recently showing difference between virus transmission in schools and
communities. (Comach et al 2008), (Mammen et al, 2009).
Asia, with more than 60 years of dengue epidemic history, had in Singapore an
example were the dengue sero-prevalence is relatively low but the public health problem
is yet important. Wilder in 2004 reported a sero-prevalence of 45 % in people from 18 to
45 years old, in a country were paradoxically Goh et al in 1997 demonstrated high
incidence of dengue cases with low density of mosquitoes. (Wilder et al 2004), (Goh et al
1997). At that age group our prevalence was over 90 %.
In Vietnam, Thai et al reported sero-prevalence of 65.7 % in schoolchildren from 7 to
14 years old. This age group and its dengue antibody prevalence were very similar to our
results in a similar group of children. (Thai et al, 2006). Graham et al in Indonesia, doing
one of the few dengue antibody sero-prevalence larger studies by PRNT, showed the
results from 1,837 children between 4 to 9 years old. Interestingly, they, like in our study,
focalized many of their results in the proportion of specific serotypes, at that age group
DENV-1 (12%) and DENV-2 (16%) were the most frequent serotypes, being 3% in
DENV-3 and 4 % in DENV-4. In contrast with our study, we were able to compare the
PRNT with the RT-PCRT results obtained in the active surveillance; we will retake this
point ahead in the discussion. Other difference with Graham’s study was that we
described the specific serotypes combination in those people results with two or more
serotypes. DENV-1 and DENV-2 was the most frequent (45%) mixture in our study
followed to DENV-1, DENV-2 and DENV-3 (17.5%) these combinations could show
that DENV-1 and DENV-2 are the viruses which have had not only more contact with
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Maracay population but also many people in Maracay would have less probability to get
sick with dangerous virus infection sequences seen in HDF. It could be an incomplete
herd immunity but enough to avoid many of the possible HDF. However, the same data
shows that an important proportion (18.9%) of the study population, and probably in the
total population of Maracay, is at risk to get HDF.
In advantage to have prospective sero-prevalence surveys through the biannual
samples, we have been able to obtain indirectly, cumulative incidence of dengue infection
from the sero-conversion detected inter each sample. In that sense, people with
monotypic sero-prevalence had the highest six month period incidence of dengue
infection. This position was repeated in the three inter biannual period of samples.
Understandably, people with multitypic sero-prevalence had less incidence of dengue
infection. For some systematic reason, people tested negative had less propensity to a
new dengue infection than people with one serotype. The people in this study shared
similar social conditions, water supply and houses characteristics so it was not our
interest to identify social aspect associated to dengue disease. However, probably
particular and personal habits could be related with this result. It is a good question to
investigate in the future. Is it an action of the age stratification? Or, do those people have
less personal risky conditions to be negative and to be less prospectively infected than
monotipyc people?
The six month incidence around 30 % was found exactly in a period of national dengue
epidemic, it could explain these huge values. The reduction to 23 % in the third inter
biannual sample is also coincident with the end of the national epidemic. Low values of
incidence of infection has been reported by Balmaseda et al in Nicaragua, with similar
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values between primary and secondary infection, probably because they did not
discriminate between people with monotypic and multitypic sero-prevalence. (Balmaseda
et al, 2006).
It has been reported the limitation that PRNT has to identify specific anti dengue
antibody serotypes when there are multiple serotypes in the sera because of cross
reactivity among them. In order to determine the precision of PRNT results in
hyperendemic population, we compared the results of confirmed dengue cases in active
surveillance by RT-PCR with the results of PRNT of each patient in the next biannual
sample. We found that PRNT has a good sensitivity to detect DENV-1 (88%), DENV-3
(78%0 and DENV-2 (69%). However, it had poor capacity to detect DENV-4 (17%).
Additionally, in other part of this study when we compare the day of IgM seroconversion in patients early confirmed by RT-PCR, it is not occurred neither in three
samples of acute phase nor convalescence phase in four from five DENV-4 infected
patients, even though it could not happen exclusively with DENV-4. New studies could
be necessary to ratify this result or to look new ways to improve the detection of DENV4.
The fact of being almost permanently close to the house of the studied people and
visiting them three or more times a week permitted us to have more than 70% of blood
samples from sick people taken before or at the third day after the onset of the symptoms,
and 97% at the fifth day. We did not find any study made in communities with those
statistics. With this information, we were able to see the proportion of confirmed dengue
cases by RT-PCR by day of sample. It did not change in the first five days, being it
around 25%. However, according to many opinions, the specificity is good until the third
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day; after that many false negative could be registered. Some surveillance systems use
RT-PCR as diagnostic method until the fifth day after the onset of the symptoms. We
found that 20% of the sample on sixth and seventh days can be positive by RT-PCR, and
it agrees with the initial authors who describe this technique. The question is: could be
RT-PCR used in routinely recommended to days six and seven. This question makes a
connection with other of our results. In conditions of low endemicity, a good combination
between RT-PCR from the first to fifth day and IgM MAC ELISA test after the fifth day
would be enough. However, we suspected and now confirmed that IgM test could reduce
its sensitivity in hyperendemic conditions and it could be so important in surveillance of
inter-epidemic periods. In our results some confirmed dengue cases never sero-converted
through the IgM MAC ELISA test, being more important in adult people. We suspected
that when the proportion of secondary infection (respect to primary infection) was higher
in IgM negative people having positive RT-PCR test than in IgM positive people in equal
condition. Supporting our assumption, several of the 17 confirmed dengue cases with
four samples tested in acute and convalescence phase of the disease never had IgM seroconversion.
Describe the clinical and hematological results considering the days in which the
symptoms and hematological changes occurred is also, in our criteria, a small
contribution of this study. Why? In the literature we can see different and sometimes
contrary results when they are reporting symptoms. In our opinion it could be caused
because those studies were made evaluating people in different moments of the disease.
Any of the reviewed papers discriminate in this single aspect. We can say that our results
are based in people who were asked about their symptoms the first days after they
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became sick. Many studies were made in people who went to the health services, and the
main symptoms in that moment could have been different to initial symptoms of the
disease. Similar cases can occur in retrospective studies, describing those main
symptoms, in terms of patient perception or medical interest, instead either the initial, or
more frequent or more specific symptoms.
Although, it is not specific, headache is a sensitive symptom in confirmed people in
initial days. Ocular pain and rash were symptoms statistically associated with dengue
disease and probably more specific than any other in the first days of the disease. We
were not in capacity to describe the clinic days after of the dengue disease evolution in
the studied people when probably other type of symptoms appeared but we can say with
security that these were the most important symptoms at the beginning of the dengue
disease. Health workers in a surveillance of dengue have to be in capacity to recognize
these differences.
In a sub sample of 50 voluntary people who were previously detected in the active
surveillance, we were able to expand the number of hematologic indicators. However,
after that, only 17 of them, those who were confirmed with dengue disease, were
followed with repeated blood samples in the short period of the disease.
Hematologic results only showed a significant reduction in the white blood cells in
confirmed people (17) compared with non confirmed people (33). We have to insist that
these samples were taken in the first days of the disease although they were enough to
illustrate that some hematologic parameters can be similar to non confirmed dengue cases
in early stages of the disease. The repeated samples in the 17 confirmed cases showed
the dynamic of the parameters although only changes in platelets and white blood cells
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were statistically significant. Interestingly, the proportion of neutrophils in relation to
lymphocytes was not reasonably higher in the sample number 1, and according to that we
could think in a bacterial infection. Nevertheless, immediately (1 or 2 days) this
proportion can change in the logical sense of a viral disease. Sometimes in stressful
situation a physician, influenced by these small clinic aspects, could change a medical
diagnostic. For that reason each small detail should be discussed in a surveillance
program.
The last part of this discussion is related with the real surveillance of the state and
country where this design was applied. In the Aragua state and similarly in Venezuela the
surveillance system is structured by the classical three level of attention: Primary,
secondary and tertiary levels. Primary level is the first step where the people have to go
when they are sick. When physicians detect possible dengue cases they report the case to
the state central health service, called CORPOSALUD in the Aragua state and
simultaneously send either the patients or their blood sample and a card with the patient
clinical and epidemiological information to LARDIDEV which is the state center to viral
diagnosis. According to the laboratory results, based mainly in IgM MAC ELISA test and
secondarily in RT-PCR and viral isolation made to a partial number of cases,
LARDIDEV classifies the patients as confirmed, probably, negative and undetermined
dengue cases. This information is reported to the epidemiological services at state and
national level. The national level of health ministry makes a public report through the
Weekly Epidemiological Bulletin. The goal of the state and national health level is to
analyze weekly the dynamic of the dengue cases, comparing the number of week cases
with an average of week cases in the last seven years. With the average and its standard
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deviation (SD) is built the endemic channel or endemic levels to establish zone of
security (between average and – 1 SD), zone of alarm (between average and + 1 SD) and
zone of epidemic (up to the 1 + SD). The expected cases in the Venezuelan endemic
channel are always higher in the rainy months (June, July, August, September, October
and November). For that reason, it is always a question if the initial increase of cases in
May and June is either the beginning of the seasonal period or the beginning of one
epidemic.
In order to compare our data with the state surveillance in this part of the study, we
defined a confirmed case as that case either with positive result of RT-PCR or viral
isolation or with sero-converted IgM dengue antibody in the period between the acute
and convalescence phase of the dengue disease.
We did not have cumulative incidence from previous years in the neighborhoods
included in the study so we decided to compare with the state and national CI in 2007.
We selected 2007 to do the comparison because it was an epidemic year, perhaps the
second huge epidemic in Venezuela in the last twenty years. In our study population, the
CI was at least 1,873 cases per 100,000 populations (47 cases in 2509 people); we said at
least 1,873 cases because we included the people who left the cohort. In other words, the
CI could be higher in our results but not less because people who left the study could
have had dengue after they were gone in the same 2007. In 2007 the Aragua state CI was
496 cases per 100,000 populations and 293 per 100,000 populations in Venezuela.
The question is if this epidemic could have been predicted. Puerto Rico has been
considered with high capacity to do it. (Gubler ) (Perez-Rigau), reporting a sensitivity of
66 % (two predictions in three epidemics) and they have been able to do the prediction
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from 4 to 8 weeks before the epidemic is installed. Puerto Rican system based this
analysis in the proportion of cases detected by virus isolation in May because they
consider May as a key month in the prediction system, being this month the beginning of
the rainy season. In Venezuela and the Aragua state, the epidemic had really begun in
October 2006 but comparing CI tendencies between 2005 and 2006 in September, it was
practically impossible to know why in 2005 the CI decreased and in 2006 increased
becoming an epidemic.
Even though our study had much more detected cases and CI in 2006 and 2007, it had
also high sample error. For instance: The study did not detect cases in May 2007. Based
in our data, we could have thought the 2007 epidemic was ending.
We thought that a prediction 8 weeks before the epidemic is good enough to activate
health service mechanisms but not to avoid it. Current active surveillance in Puerto Rico
and most of the countries with passive surveillance system are structured to predict
(Puerto Rican situation) or identify epidemics but any of these surveillance system has
been thought to understand the virus transmission, different levels of people at risk, and
which could be the impact of a new epidemic in a specific population. Consequently, it is
also important to make surveillance of factors and interventions in endemic populations.
Since epidemics in Singapore has been related with low densities of vector, other studies
have found evidence that partial successful programs of mosquito control could have
unexpected and contrary effects, increasing the incidence of severe forms of dengue
disease. Partially, it explains the complex mechanism of the virus transmission which
should be also followed-up by surveillance programs. In addition, the Basic
Reproductive Number (BRN) has been considered an essential element to be applied in

112

disease control and evaluation of vaccination programs. However, it is uncertain what the
role of unapparent infeccion people could have to establish the BRN. To respond the
question could be very important in a new dengue vaccine era. How many or what
percentage of individuals should be vaccinated to obtain successful dengue herd
immunity?
Summarizing the Defense
One of the aspects more discussed in the defense of the dissertation was that in a high
proportion of confirmed dengue cases the sero-conversion of IgM anti dengue antibody
never was reached. This result was supported either by the active surveillance or by the
biannual sample. The importance of this point is because the IgM is considered the
angular stone in the surveillance of dengue epidemic in a population. In addition, it has
clinical implication due to the probable low specificity of this test. Its result could be
explained by the huge proportion of secondary infection of dengue in the study
population where the IgG anti dengue antibody could veiled the IgM response. For any
explanation this outcome suggests the necessity of early detection of dengue cases using
RT-PCR especially in interepidemic periods where the confirmation of the cases is very
important.
Other significant issue discussed in the defense was the coincidence between the
surveillance in the study design with the real surveillance in the city of Maracay in the
same period of time. The real dengue epidemic in Maracay city in 2007 was reflected
similarly in the study in the four sample population of the “Barrios”. In 2007 the peak of
cases and incidence of dengue occurred in the months of higher rain (July and August)
similarly to the historic increase of cases in Aragua state from 2005 to 2007. However,
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either in the study or in the regular surveillance it is difficult to predict when the increase
of the case will be caused by the epidemic or by the rain effect.
One question was related about the people lost in the study, around 22 % in the two
years of the study, being this lost higher in adults with 22 % than children with 14 %.
This study was made in poor neighborhoods where there is a high mobility of the adults
looking for better economic incomes.
Other question in the defense was why DENV-1 was more present in adults and why
DENV-3 was similar in adults and children. Since 1989, when the first big epidemic of
Dengue Hemorrhagic Fever was described in Venezuela, DENV-1 always has been
present; therefore, many adults have actually antibodies against this serotype and children
have been less exposed to DENV-1. In the other hand, epidemic of DENV-3 had not been
described in Venezuela until 2001 when a huge epidemic occurred, as a result children
and adults were exposed similarly and it is the probable reason that DENV-3 has similar
proportion of infection in both age groups.
How the results of this study could impact the surveillance system in the state of
Aragua?
The passive surveillance is the current system in Aragua state and it is useful only to
detect the initial growth of the epidemic and prepare the health services to reduce its
impact. This study, made in small areas of population and communities, could be a model
of sentinel surveillance to detect the real impact of the virus circulation, detecting the real
number of asymptomatic people. This people could be an important factor in the
transmission of the disease. In terms of control, the surveillance of the vector along with
the human surveillance is a necessary strategy to improve the impact of the disease. The

114

only reduction of the vector index is not enough to reduce the risk of DHF because
simultaneously it could increase the number of susceptible people. The control of the
vector has to be almost one hundred percent effective, permanent and integrated with the
active surveillance if we really want to avoid worst situations of dengue epidemic in the
future.
This sentinel groups from specific endemic areas could also identify people with
different number of antibodies anti dengue and people without antibodies anti dengue to
determine where the risk of DHF is higher.
.
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CHAPTER SIX: CONCLUSIONS
This was the first follow-up study of dengue disease made in Venezuela since it reemerged in 1989. There have been other prospective dengue studies in this country but
based in repeated surveys of seroprevalence. Similarly, few studies in the Americas have
been designed to establish dengue incidence, identifying and following previously the
healthy people at risk. It is also the first time in Venezuela and probably in Latin
America that the Incidence Density is established in a high risk population of dengue.
Other studies from the Americas and Asia have described the frequency of unapparent
dengue infection, estimating the disease incidence based in cases reported from schools,
workplaces or health service centers but very few of them have obtained the people
information directly from their houses and communities. It permitted us to reduce the
time when the sick people was recognized and registered. For example to know exactly if
a person was really asymptomatic when he or she was infected by the dengue virus.
This study analyzed three particular aspects of dengue disease: epidemiology,
diagnosis, and clinical of the people in the follow-up. All of them were considered in the
framework of the public health surveillance.
From the epidemiological point of view we described the dengue disease according to
temporal variable, determining the disease frequency in years and months. Personal
factors were studied through the age groups, gender and immunological history of
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infection variables. Finally, the space variable was described through the four
hyperendemic neighborhoods in the endemic city of Maracay.
Laboratory diagnosis was analyzed according to: the dynamic of the surveillance, type
of test, the day of the diagnosis and its interrelation with personal factors, mainly age
groups and immunological status. In the same way, some clinical aspects were analyzed
trying to link them with the surveillance strategy.
We obtained the first ID values of dengue disease in sample population from a
hyperendemic city in Venezuela. 5.69 per 100,000 p/d in the first year of study (Sep.
2006 to Sep. 2007), being this years coincident with a national dengue epidemic, and 1.45
per 100,000 p/d in the second year (Sept 2007 Sep. 2008) when the epidemic
disappeared. In addition, for the first time we obtained a direct and significant higher
Relative Risk in children. In the first year the RR was 4.77 and 2.52 in the second one.
All these results were valuables for us because we had an important validity aspect in the
study; we were able to demonstrate when the people were really symptomatic; even
though sample error had to be present in our results. Comparing with the state massive
and passive surveillance system, in this study the advantage that we lost in precision was
probably earned in validity.
Cumulative Incidence and Incidence Density are different measures and have different
goals. However, thinking how to visualize the ID values found in this study, we showed
this example: 274 people followed-up by 365 days (one year) represents around 100,000
person days of follow-up. Then, if all 274 finished a supposed study period, we could
obtain ID and CI independently. In one year, 2 cases of any disease will correspond not
only with a CI of 730 per 100,000 populations but also with an ID of 2 cases per 100,000
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p/d. In our study we did not have fixed population but this example permitted us to have
an idea in terms of magnitude about what an ID of 1 or 2 or 15 means.
We had two important limitations in this part of the study. The first one, we did not
include children less than 5 years old. Future studies have to include this special age
group of risk, by no published reports we know that a high proportion of children was
born with mother IgG dengue antibody and it should be affecting the crude incidence of
the disease. The second limitation was that we studied only hyperendemic communities;
we should have had comparative non hyperendemic communities to see how different the
incidence among them could be.
In our opinion, public health surveillance, in a big city as Maracay, should have at least
two samples of population (with high and low incidence), like sentinel surveillance. It
could detect new changes in the virus transmission, changes in the expected incidence
and validate information obtained in massive and passive surveillance system.
We were able to demonstrate that either IgM sero-prevalence or PRNT sero-prevalence
evidenced high proportion of asymptomatic infection of dengue. Thereby, systematic
surveys of IgM sero-prevalence in supposed healthy people, in a complementary
surveillance strategy, could be a less time consuming and cheaper way to track and
estimate the virus dynamic in the entire population. Smaller sub samples tested by PRNT
would be used to validate this information.
Even supposing IgM seroprevalence could be a good indicator of unapparent infection,
we also demonstrated that IgM was not able to detect an important number of infected
people by dengue virus when they were secondarily infected. Considering hyperendemic
population in a surveillance system with high proportion of secondary infection, precise
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laboratory strategies should be implemented. We propose to investigate a little expansion
in the days to test RT-PCR; it could improve the surveillance sensitivity by confirmed
dengue cases.
The analysis of serotype infection by age groups permits us to conclude that DENV-1
and DNEV-2 have been the two specific causes of dengue infection in the last 20 or 30
years in the sample studied and probably a good estimation of the hyperendemic
neighborhoods of Maracay city. As a result, children have shown to be less protected
against those serotypes and then higher proportions of those dengue serotypes cases were
detected in them. In a surveillance system historical registrations of these proportions and
values could be appreciated to detect changes by the action of new serotypes and
potential new genotypes. We cannot demonstrate a spatial distribution of specific
serotypes, and again our study limitation having only high endemic areas kept the
question if there would be different distribution of serotypes depending on the incidence
level of the community.
Another remarkable conclusion is that 86% of studied people have been infected by
dengue virus and 68% have been infected by two or more serotypes, finally, 63% of the
total study population was infected by DENV-1 and DENV-2.
Our sample size was big enough to estimate the DF cases but it was relatively small to
have a significant number of HDF cases. Unfortunately we cannot look for association
between number and serotypes sequences of previous dengue infection and clinic
severity. On the other hand, fortunately enough percentage of multitypic infection could
have protected the people against severe forms of dengue.
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By two different results, we found similar inconsistency whit DENV-4 serotype
identification. Contrary with the others serotypes, PRNT results detecting DENV-4 were
incongruent with the RT-PCR made in active surveillance to detect disease incidence.
Additionally, four from five RT-PCR DENV-4 positive cases did not sero-converted in
three acute samples and one convalescence sample tested by IgM MAC ELISA. These
preliminary results could be a sufficient argument to investigate the DENV-4
immunological behavior.
Reasonably, a person with one serotype should have less probability (3 from 4
serotypes) to get a new dengue infection than those people with negative results to antidengue antibodies at risk to get 4 from 4 serotypes. However, consistently, our results
showed that people with one serotype were more frequent infected by a second dengue
serotype than people that have never been in contact with the virus. This is a conclusion
but is also a question to be answered in a next investigation.
Our results, according to clinical symptoms associated with dengue confirmed cases,
have to be understood in the framework of the short period in which the cases were
detected and confirmed. That means that 72 % of our cases were detected by active
surveillance in the third day or before after the onset of the symptoms, and 96 % equal or
before to the fifth day after the onset of the symptoms. Therefore, we made emphasis to
describe those early symptoms of dengue disease. Those symptoms which should appear
in the late acute phase of the disease were not described in this study.
On one hand headache was the most sensitive symptom present in more than 94 % of
the confirmed cases. On the other hand, ocular pain and rash were independently
associated with dengue confirmed cases.
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In the surveillance system health workers should be ready to differentiate the
symptoms when the patients are coming in early or in late acute phase of the dengue
disease.
The incidence of dengue cases detected by this study in the last trimester of 2006 and
2007 was higher than the incidence of 2008. This incidence dynamic was similar to the
national incidence and Aragua state incidence which identified the epidemic in 2006 and
2007 hence we were also able to identify the 2006-2007 epidemic in our study
population. However, the study sample was probably affected by the sample error and we
could not see cases in May 2007 so it could have been understood like the epidemic was
ending. In conclusion a sample size around 3,000 people could not be enough to have a
monthly number of dengue cases to detect changes in an epidemic dynamic. Passive
surveillance in the country or state is working with the total population therefore the
sample error is practically zero and good indicator of the incidence dynamic. We believe
the use of small sample size like sentinel group of surveillance can help but is not the
fundamental point in the system to identify or predict epidemics. Smaller groups of
sentinel active surveillance may help in those aspects where massive procedure cannot
identify clue elements of the analysis.
A parallel discussion is the capacity to predict or identify epidemics. We thought that
passive surveillance system can only identify but not predict epidemic. Therefore, it is in
these cases of prediction and prevention where close active and sentinel surveillance of
key and usually hidden aspects would be necessary.
Unfortunately, the dengue surveillance systems in Latin America and probably in other
developing countries in the world are not structured to either prevent dengue epidemic or
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improve endemic situations. Basically their function and goals are to detect epidemics in
the initial stage to prepare hospitals, health workers and communities in response to that
situation. However, real advantages of new surveillance strategies are not being wellspent to improve the control and prevention of dengue disease.
In a near future we have to include new procedures in the surveillance of dengue and
this study was oriented to help in that sense.
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APENDIX A: Map of Venezuela, Aragua State and their Municipalities.

The two municipalities in the study.
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Municipalities: Bolivar (1), Camatagua (2), Girardot (3), J.F. Rivas (4), L. Alcántara (5), Lamas (6),
Libertador (7), M.B. Iaragorry (8), Mariño (9), Revenga (10), San Casimiro (11), S. Michelena (12), S.
Sebastián (13), Sucre (14), Tovar (15), Urdaneta (16) y Zamora (17).
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APENDIX B: Maracay city and the Four Barrios:

Population: 12,722
Sample: 628

Population: 16,996
Sample: 635

“Piñonal”
“La Cooperativa”
Total Population in the four
“Barrios”: 103,958
Total sample: 3,225

“23 de Enero”
Population: 15,718
Sample: 693

“Caña de Azucar”
Population: 58,522
Sample: 1,299
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APENDIX C: Maracay monthly mean total precipitation (mm)

Venezuela
Venezuela Air Force Weather Service
Weather Information for

Maracay

Climatological Information
Mean Temperature oC

Mean Total
Mean Number of
Daily
Precipitation (mm) Precipitation Days
Maximum

Month

Daily
Minimum

Jan

15.5

34.0

3.5

2

Feb

16.3

35.0

4.5

1

Mar

17.0

36.0

7.0

2

Apr

19.0

35.5

45.2

6

May

20.4

33.7

105.5

13

Jun

19.5

32.9

133.3

16

Jul

19.0

31.6

129.1

17

Aug

19.2

32.3

172.4

18

Sep

19.3

32.1

135.2

16

Oct

19.0

32.5

99.0

14

Nov

18.6

32.8

51.5

10

15.3

4

15.4
32.9
Dec
>> Click here for temperatures in oF

Remarks:
* Climatological information is based on monthly averages for the 30-year period 19611990.
* Mean number of precipitation days = Mean number of days with at least 1 mm of
precipitation.
* Precipitation includes both rain and snow.
* Attention: Please note that the averaging period for climatological information and the
definition of "Mean Number of Precipitation/Rain Days" quoted in this web site may be
different for different countries. Hence, care should be taken when city climatologies
are compared.
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APPENDIX D: Clinic epidemiologic card of febrile syndrome.
EPIDEMIOLOGICAL CLINICAL INVESTIGATION OF FEBRILE SYNDROME
Interview date ___/___/___
Epidemiological week ______________
( ) ACUTE SAMPLE (complete the questionaire-collect convalescent sample two/three weeks after onset of symptoms)
( ) CONVALESCENT SAMPLE: Total duration of symptoms _____ still symptomatic ( ) if it is convalescent, APPLY CODE ON ACUTE SAMPLE:______
Demographic Data

ANSWER YES OR NOT ON EACH CASE

Last name
First name
Date:
___/___/___
Health center

Age:

Sex:
1M( ) 2F( )

Actual address
District

Province

Department.

Phone number

PAST HISTORY
Ocupation _______________________
Vaccines received:
Yellow Fever:
Hepatitis:
NO ( ) YES ( )
NO ( ) YES ( )
Date ___/___/___
Date ___/___/___
Place of residence for the last 60 days:
Locality: ________________________
District: __________________________
Trips in the last 30 days:
Locality: __________________________
District: ___________________________

CLINICAL DATA
Clinical History Number _______________
Date of symptom onset: ___/___/___
Date of second evaluation: ___/___/___

Temperature
Shivers
General Malaise
Hiporrhexia
Asthenia
Prostracion
Weight loss
Palor
Conjuntival Injection
Epistaxis
Gingivorragia
Ecchymosis
Petequiae
Purpura
Vaginal bleeding
Maculopapular Rash
Facial Erythema
Central Rash
Distal Rash
Vesicles
Subcutaneous
nodules
Facial edema
Lower limbs edema
Soft tisues
edema
Joint inflamation
Arthralgias
Myalgias
Bone pain
Joint function
incapacity
Adenopathy

1st Eval.
( )___ºC

2nd Eval.
( )___ºC

(Yes)

(NO)

(Yes)

(NO)

(Yes)

(NO)

(Yes)

(NO)

(Yes)

(NO)

(Yes)

(NO)

(Yes)

(NO)

(Yes)

(NO)

(Yes)

(NO)

(Yes)

(NO)

(Yes)

(NO)

(Yes)

(NO)

(Yes)

(NO)

(Yes)

(NO)

(Yes)

(NO)

(Yes)

(NO)

(Yes)

(NO)

(Yes)

(NO)

(Yes)

(NO)

(Yes)

(NO)

(Yes)

(NO)

(Yes)

(NO)

(Yes)

(NO)

(Yes)

(NO)

(Yes)

(NO)

(Yes)

(NO)

(Yes)

(NO)

(Yes)

(NO)

(Yes)

(NO)

(Yes)

(NO)

(Yes)

(NO)

(Yes)

(NO)

(Yes)

(NO)

(Yes)

(NO)

(Yes)

(NO)

(Yes)

(NO)

(Yes)

(NO)

(Yes)

(NO)

(Yes)

(NO)

(Yes)

(NO)

(Yes)

(NO)

(Yes)

(NO)

(Yes)

(NO)

(Yes)

(NO)

(Yes)

(NO)

(Yes)

(NO)

(Yes)

(NO)

(Yes)

(NO)

(Yes)

(NO)

(Yes)

(NO)

(Yes)

(NO)

(Yes)

(NO)

(Yes)

(NO)

(Yes)

(NO)

(Yes)

(NO)

(Yes)

(NO)

(Yes)

(NO)

(Yes)

(NO)
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Digestive System/Abdomen
1º Eval.
2º Eval.
Abdominal pain
(Yes) (NO) (Yes) (NO)
Diarrhea
(Yes) (NO) (Yes) (NO)
Nausea
(Yes) (NO) (Yes) (NO)
Vomiting
(Yes) (NO) (Yes) (NO)
Melena
(Yes) (NO) (Yes) (NO)
Hematochezia
(Yes) (NO) (Yes) (NO)
Ascites
(Yes) (NO) (Yes) (NO)
Abdominal distention (Yes) (NO) (Yes) (NO)
Hepatomegaly
(Yes) (NO) (Yes) (NO)
Splenomegaly
(Yes) (NO) (Yes) (NO)
Icterus
(Yes) (NO) (Yes) (NO)
Hepatojugular
Reflux
(Yes) (NO) (Yes) (NO)
Cardio-Respiratory System
Congestiva Pharynx
Rhinorrhea
Coughing
Expectoration
Polipnea
Dyspnea
Wheezing
Cyanosis
Roncors
Crepitus
Pulmonar murmur
Pulmonary murmur
Cardiac murmur
Jugular regurgitation
Gallop
Arritmia

(Yes)

(NO)

(Yes)

(NO)

(Yes)

(NO)

(Yes)

(NO)

(Yes)

(NO)

(Yes)

(NO)

(Yes)

(NO)

(Yes)

(NO)

(Yes)

(NO)

(Yes)

(NO)

(Yes)

(NO)

(Yes)

(NO)

(Yes)

(NO)

(Yes)

(NO)

(Yes)

(NO)

(Yes)

(NO)

(Yes)

(NO)

(Yes)

(NO)

(Yes)

(NO)

(Yes)

(NO)

(Yes)

(NO)

(Yes)

(NO)

(Yes)

(NO)

(Yes)

(NO)

(Yes)

(NO)

(Yes)

(NO)

(Yes)

(NO)

(Yes)

(NO)

(Yes)

(NO)

(Yes)

(NO)

(Yes)

(NO)

(Yes)

(NO)

Urogenital System
1º Eval.

2º Eval.
Dysuria
(Yes) (NO) (Yes) (NO)
Oliguria
(Yes) (NO) (Yes) (NO)
Polyuria
(Yes) (NO) (Yes) (NO)
Constipation
(Yes) (NO) (Yes) (NO)
Urinary urgency
(Yes) (NO) (Yes) (NO)
PPL
(Yes) (NO) (Yes) (NO)
Cervix tender to
movement
(Yes) (NO) (Yes) (NO)
Leukorrhea
(Yes) (NO) (Yes) (NO)
Pelvic pain
(Yes) (NO) (Yes) (NO)
Concrete mass
(Yes) (NO) (Yes) (NO)
Nervous system
Conciousness
disorder
(Yes) (NO) (Yes) (NO)
Headache
(Yes) (NO) (Yes) (NO)
Seizures
(Yes) (NO) (Yes) (NO)
Neck stiffness
(Yes) (NO) (Yes) (NO)
Focalizing signs
(Yes) (NO) (Yes) (NO)
Others
Retroocular pain
Otorrhea
Ear pain

(Yes)

(NO) (Yes)

(NO)

(Yes)

(NO) (Yes)

(NO)

(Yes)

(NO) (Yes)

(NO)

OUTCOME
CURED
RECOVERED
DEAD (Date) ___/___/___
Possible diagnosis
Name of health provider:
______________________________

APPENDIX E: Inform Consent Adult
ADULT CONSENT FORM
Longitudinal Serology Survey
CONSENT FORM
Laboratorio Regional de Diagnostico e Investigacion del Dengue y otras Enfermedades
Virales y el Centro de Investigaciones Biomedicas de la Universidad de Carabobo,
Maracay, Venezuela (LARDIDEV/BIOMED-UC)
Naval Medical Research Center Detachment, Lima, Peru (NMRCD)
Walter Reed Army Institute of Research, USA (WRAIR)
Persons of 18 years or older
Consent to Participate in a Research Study
Project Title: Active Dengue Surveillance and Predictors of Disease Severity in Maracay, Venezuela.
Project House Code: _____________

Participant ID No. __________

1. PURPOSE: LARDIDEV/BIOMED-UC, NMRCD and theWRAIR are carrying out a research study called “Active
Dengue Surveillance and Predictors of Disease Severity in Maracay, Venezuela.” The purpose of this study is to
determine what type of dengue virus is transmitted in Maracay and how severe is the disease presentation with that
virus type. We would like to ask you to volunteer to take part in this research project, which will include about 3500
people and it will last about 3 years.
2. PROCEDURES: If you decide to participate in the study, there are two possible levels of participation from which
you may choose. The first option is that we will ask you for a small sample of blood every six months for the next 3
years and allow us to visit to your house 3 times a week to ask if anyone in the house has a fever or other illness. The
second option is to simply allow us to visit to your house 3 times a week to ask if anyone in the house has a fever or
other illness.
An experienced laboratory technician or a study physician will take the blood samples. The six-month blood samples
will be 5 ml (1.25 teaspoons). The first sample will be used to determine if you have had dengue in the past and if you
have had dengue which type of virus it was. The subsequent samples will be used to determine if you have had dengue
(and if so what type of virus) during the last sampling period.
Study personnel will visit your house 3 times each week to ask if anyone in the house has a fever or other illness. If
anyone with fever or history of fever is found, you/they will be invited to participate in an additional study where a
blood sample (5 ml, 1.25 teaspoons) will be taken from your/their arm (venipuncture), and a physician free of charge
will examine you/them. A study worker will visit your house daily until you/they are well. During the daily visits a
study worker will take your/their temperature, vital signs, ask some questions about how you/they feel, and carry out a
tourniquet test. The tourniquet test is used to look for signs of serious illness and applies pressure to the upper arm
using a blood pressure cuff. A final sample of blood will be requested 10 to 21 days later. Your/their blood will be
used to attempt to isolate virus from the first sample and to identify dengue antibodies from both the first and last
specimens.
3. RISK TO PARTICIPANT: Blood will be drawn from your arm with a needle by an experienced laboratory
technician or physician. The risk that you may be injured during collection of blood is minimal, but it is possible that
there may be some pain and discomfort when the blood is removed from your arm; afterwards there may be some
bruising or swelling and a very small possibility of infection at the site where the blood was collected. You may feel
faint when the sample is taken but this is uncommon and the feeling will pass quickly. The dengue tourniquet test can
cause arm pain in some people while the blood pressure cuff is inflated. This pain goes away when the cuff is deflated.
While the cuff is inflated the skin on your arm and hand below the cuff may appear discolored (red, blue, purple). This
discoloration will clear up after the cuff is deflated. You may develop a rash on your forearm appearing as many small
red dots. This rash will disappear after a few days.
4. POTENTIAL BENEFITS: The possible benefits to you from taking part in this study include: the blood samples
you give will tell you if you have had dengue (but will not prevent the disease directly) and the wellness visits to your
home by a study physician at the time of illness may provide you with timely referral for medical care.
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5. COST AND COMPENSATION: There is no cost to you to participate in the study.
6. MEDICAL CARE FOR RESEARCH RELATED INJURY: If you are injured as a direct result of taking part in this
research project, you will be given medical care for that injury. This will be given to you at no cost to you. You will
not receive any injury compensation, only medical care. You should discuss this issue thoroughly with the study
personnel before you enroll in this study. Signing this document does not limit your rights to seek legal remedies
through the Venezuelan legal system.
7. SUBJECT CONFIDENTIALITY: All the information related to this project will be confidential. The documents of
this research study will be kept at the LARDIDEV/BIOMED-UC office in Maracay and at the NMRCD office in Lima.
The data may be reviewed by the Institutional Review Board of the Naval Medical Research Center, Silver Spring,
Maryland, USA and by the BIOMED-UC Investigation Ethics Committee. We will keep them private to the extent
legally possible.
8. VOLUNTARY PARTICIPATION: You can decide not to take part in this study or you can leave this study at
anytime without any negative consequences.
9. POINTS OF CONTACT: If you want to talk to someone about this study or if you have been injured from taking
part in this study, please contact: Dr. Guillermo Comach at LARDIDEV/BIOMED-UC at 0-416-543-2116. If you have
any questions about your rights as a participant, contact Dr. Silvia Montano, of NMRCD-Peru, at 011-511-561-2733.
10. ADULT CONSENT: Signing below indicates that the study has been explained to you and that you agree to take
part at no cost to you or your family, or others living in the house. Additionally, your signature indicates that you have
had the chance to ask questions. You should know that any questions that you may have in the future will be answered
by one of the study investigators, and that you have informed all adult members of the household about the study. You
will be given a copy of the consent form so that you have this information.
I agree to have blood samples taken _______. I prefer not to give blood samples _______.
Initials
Initials
It is possible that after we have completed the laboratory tests on your blood samples that there will be some leftover.
What do you what us to do with your leftover blood samples? Initial only one option.
________ After the study is completed destroy all remaining specimens.
Initials
________ After the study is complete the remaining specimens can be used for any scientific purpose
Initials provided that the scientific purpose is approved by an Institutional Review Board and that my
specimen will not be identified by my name but only by a number. I also understand that there will be
no compensation for the future use of my specimen(s).
If you change your mind, at any time, and would like your leftover blood samples destroyed contact Dr. Guillermo
Comach at 0-416-543-2116.
11. ADULT HEAD OF HOUSEHOLD CONSENT: Signing below indicates that the study has been explained to you
and that you agree to take part at no cost to you or your family, or others living in the house. Additionally, your
signature indicates that you have had the chance to ask questions. You should know that any questions that you may
have in the future will be answered by one of the study investigators, and that you have informed all adult members of
the household about the study. You will be given a copy of the consent form so that you have this information.
I agree that my household will participate in the project ___________.
Initials
Name of Participant: _____________________________________ Age__________
Signature of Participant: _________________________________ Date __________
If the Participant is illiterate an adult must witness the consent process.
Name of Witness: _______________________________________ Age___________
Signature of Witness ____________________________________ Date ____________
Name of Investigator: _____________________________________
Signature of Investigator _________________________________ Date ____________
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APPENDIX F: Inform Consent Children
PARENTAL CONSENT FORM (Longitudinal Serology Survey)
CONSENT FORM
Laboratorio Regional de Diagnostico e Investigacion del Dengue y otras Enfermedades
Virales y el Centro de Investigaciones Biomedicas de la Universidad de Carabobo,
Maracay, Venezuela (LARDIDEV/BIOMED-UC)
Naval Medical Research Center Detachment, Lima, Peru (NMRCD)
Walter Reed Army Institute of Research, USA (WRAIR)
Parental Consent for children 5-17 years of age
Consent to Participate in a Research Study
Project Title: Active Dengue Surveillance and Predictors of Disease Severity in Maracay, Venezuela.
Project House Code: _____________

Participant ID No. __________

1. PURPOSE: LARDIDEV/BIOMED-UC, NMRCD and the WRAIR are carrying out a research study called “Active
Dengue Surveillance and Predictors of Disease Severity in Maracay, Venezuela.” The purpose of this study is to
determine what type of dengue virus is transmitted in Maracay and how severe is the disease presentation with that
virus type. We would like to ask your child/children to volunteer to take part in this research project, which will
include about 3500 people and it will last about 3 years.
2. PROCEDURES: If you agree to your child’s/children’s participating in this study, we will ask your child/children
for a small sample of blood every six months for the next 3 years and allow us to visit to your house 3 times a week to
ask if anyone in the house has a fever or other illness.
An experienced laboratory technician or a study physician will take the blood samples. The six-month blood samples
will be 3 ml (0.6 teaspoons). The first sample will be used to determine if your child/children has/have had dengue in
the past and if your child/children has/have had dengue which type of virus it was. The subsequent samples will be
used to determine if your child/children has/have had dengue (and if so what type of virus) during the last sampling
period.
Study personnel will visit your house 3 times each week to ask if anyone in the house has a fever or other illness. If
your child/children is with fever or history of fever is found, your child/children will be invited to participate in an
additional study where a blood sample (3 ml, 0.6 teaspoons) will be taken from their arm (venipuncture), and a
physician will examine them free of charge. A study worker will visit your house daily until they are well. During the
daily visits a study worker will take their temperature, vital signs, ask some questions about how they feel, and carry
out a tourniquet test. The tourniquet test is used to look for signs of serious illness and applies pressure to the upper arm
using a blood pressure cuff. A final sample of blood will be requested 10 to 21 days later. Their blood will be used to
attempt to isolate virus from the first sample and to identify dengue antibodies from both the first and last specimens.
3. RISK TO PARTICIPANT: Blood will be drawn from your child’s/children’s arm with a needle by an experienced
laboratory technician or a physician. The risk that they may be injured during collection of blood is minimal, but it is
possible that there may be some pain and discomfort when the blood is removed from their arm; afterwards there may
be some bruising or swelling and a very small possibility of infection at the site where the blood was collected. They
may feel faint when the sample is taken but this is uncommon and the feeling will pass quickly. The dengue tourniquet
test can cause arm pain in some people while the blood pressure cuff is inflated. This pain goes away when the cuff is
deflated. While the cuff is inflated the skin on their arm and hand below the cuff may appear discolored (red, blue,
purple). This discoloration will clear up after the cuff is deflated. They may develop a rash on their forearm appearing
as many small red dots. This rash will disappear after a few days.
4. POTENTIAL BENEFITS: The possible benefits to your child/children from taking part in this study include: the
blood samples they give will tell them if they have had dengue (but will not prevent the disease directly) and the
wellness visits to your home by a study physician at the time of illness may provide you with timely referral of your
child/children for medical care.
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APPENDIX F: Continued
5. COST AND COMPENSATION: There is no cost to you or to your child/children to participate in the study.
6. MEDICAL CARE FOR RESEARCH RELATED INJURY: If your child/children is/are injured as a direct result of
taking part in this research project, they will be given medical care for that injury. This will be given to them at no cost
to you. They will not receive any injury compensation, only medical care. You should discuss this issue thoroughly
with the study personnel before you enroll your child/children in this study. Signing this document does not limit
your/their rights to seek legal remedies through the Venezuelan legal system.
7. SUBJECT CONFIDENTIALITY: All the information related to this project will be confidential. The documents of
this research study will be kept at the LARDIDEV/BIOMED-UC office in Maracay and at the NMRCD office in Lima.
The data may be reviewed by the Institutional Review Board of the Naval Medical Research Center, Silver Spring,
Maryland, USA and by the BIOMED-UC Investigation Ethics Committee. We will keep them private to the extent
legally possible.
8. VOLUNTARY PARTICIPATION: Your child/children can decide not to take part in this study or they can leave
this study at anytime without any negative consequences.
9. POINTS OF CONTACT: If you want to talk to someone about this study or if your child/children has been injured
from taking part in this study, please contact: Dr. Guillermo Comach at LARDIDEV/BIOMED-UC at 0-416-5432116. If you have any questions about your rights as a participant, contact Dr. Silvia Montano, of NMRCD-Peru, at
011-511-561-2733.
10. CONSENT: THE PROJECT HAS BEEN EXPLAINED TO YOUR CHILD/CHILDREN IN YOUR PRESENCE
IN A LANGUAGE AND LEVEL HE/SHE/THEY CAN UNDERSTAND. HE/SHE/THEY HAS/HAVE BEEN
ENCOURAGED TO ASK QUESTIONS ABOUT THE RESEARCH STUDY. YOUR SIGNATURE BELOW WILL
SHOW THAT YOU HAVE CONSENTED TO LET YOUR CHILD/CHILDREN VOLUNTEER TO TAKE PART IN
THIS STUDY.
1 ______________________________________________________________________________________
Name of child
Age of Child
Signature of Parent or Guardian
2 ______________________________________________________________________________________
Name of child
Age of Child
Signature of Parent or Guardian
3 _____________________________________________________________________________________
Name of child
Age of Child
Signature of Parent or Guardian
4 _____________________________________________________________________________________
Name of child
Age of Child
Signature of Parent or Guardian
It is possible that after we have completed the laboratory tests on your child’s/children’s blood samples that there will
be some leftover. What do you want us to do with their leftover blood samples? Initial only one option.
________ After the study is completed destroy all remaining specimens.
Initials
________ After the study is complete the remaining specimens can be used for any scientific purpose
Initials
provided that the scientific purpose is approved by an Institutional Review Board and that my
child’s/children’s specimen will not be identified by their name but only by a number.
I also understand that there will be no compensation for the future use of their specimen(s).
If you change your mind, at any time, and would like their leftover blood samples destroyed contact Dr. Guillermo
Comach at 0-416-543-2116.
If the parent or guardian is illiterate an adult must witness the consent process.
Name of Witness: _______________________________________ Age___________
Signature of Witness ____________________________________ Date ____________
Name of Investigator: _____________________________________
Signature of Investigator _________________________________ Date ____________

141

About the Author

Carlos Espino received a Medical degree from the University of Carabobo, Venezuela
in 1985 and a Master of Science in Occupational Health at the same university in 1994.
In 2004 he received a Master of Science Diploma in Public Health at the University of
South Florida. He is a full professor in the Public Health Department at the University of
Carabobo since 1992, where he was Department chief in 1998.
Since 2006, Espino is part of the team of the Institute of Biomedical Research
(BIOMED) at the University of Carabobo, in the laboratory of dengue and other viral
diseases.

